

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number  
WO 2004/026895 A2

(51) International Patent Classification?: C07K 7/04,  
7/64, A61K 38/04

H3G 1Y6 (CA). SARAGOVI, H., Uri [US/CA]; McGill  
University, Pharmacology and Therapeutics, 3655 Drum-  
mond St., #1320, Montreal, Québec H3G 1Y6 (CA).

(21) International Application Number:  
PCT/CA2003/001389

(74) Agent: SMART & BIGGAR; Attn.: Kingwell, Brian, G.,  
Box 11560, Vancouver Centre, 2200 - 650 West Georgia  
Street, Vancouver, British Columbia V6B 4N8 (CA).

(22) International Filing Date:  
19 September 2003 (19.09.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT (util-  
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (util-  
ity model), DE, DK (utility model), DK, DM, DZ, EC, EE  
(utility model), EE, EG, ES, FI (utility model), FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,  
SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/412,492 20 September 2002 (20.09.2002) US

(71) Applicant (*for all designated States except US*): MCGILL  
UNIVERSITY [CA/CA]; Office of Technology Transfer,  
3550 University Street, Montreal, Québec H3A 2A7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GAGNON, Mar-  
tin [CA/CA]; McGill University, Pharmacology and Ther-  
apeutics, 3655 Drummond St., #1320, Montreal, Québec

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: GD2 LIGANDS

mgadgetvvl knmliginli llgsmikpse cqlevtterr qrqsveee gg ianynts ske 61  
qpvvfnhvyn invpldnls sgleasaeg vsaedetlae ymgqtsdhes qvtffthrinf 121  
pkkacpcass aqvlqellsr iemlerevsv lrdqcnancc qesaatgqld yiphcsghgn 181  
fsfescgcic negwfgkncs epycplgcss rgvcvdgqci cdseysgddc selrcptdcs 241  
srglcvdgc vcepytged crelrcpgdc sgkgrcangt clceegyvge dcgqrqclna 301  
csgrgqceeg lcvceegyqg pdcsavappe dlrvagisdr sielewdgpm avteyvisyq 361  
ptalgglqlq qrvpgdwsgv titelepglt ynisyvavis nilslpitak vathlstppg 421  
lqfktitett vevqwepfsf sfdgweisfi pknneggvia qvpsdvtsfn qtglkpgeey 481  
ivnvvalkeq arspptsasv stvidgptqi lvrdivsdtva fvewipprak vdfillkygl 541  
vggeggrttf rlqpplsqys vqalrpgsry evsvsavrgr nesdsattqf tteidapknl 601  
rvgsrtatsl dlewdnseae vqeykvyst lageqyhevl vprgigpitr atldtlvpgt 661  
eygvgisavm nsqsvpatm narteldspr dlmvtasset sisliwtkas gpidthyritf 721  
tpssgiasev tvpkdrtsyt ltdlepgae yisvtaergr qqslestvda ftgfrpishl 781  
hfshvtsssv nitwsdpssp adrlilnysp rdeeeemnev sldatkrhav lmglqpatey 841  
ivnlvavhgt vtsepivgsi ttgidppkdi tisnvtkdsv mvswsppvas fdyyrvsyrp 901  
tqvgrldssv vpntvtefti trlnpateye islnsvrgre eserictlvh tamdnvpdli 961  
atnitpteal lqwkavpgev enyvivilthf avagetilvd gvseefrlvd llpsthytat 1021  
myatngplts gtistnfstl ldppanltas evtrqsalis wqppraeien yvltystdg 1081  
srkelivdae dtwirlegl entdytvlq aaqdttwssi tstafttggr vfphpqdcaq 1141  
hlmgqdtlsg vypiflngel sqklqvycdm ttdgggwivf qrrqngqtdf frkwadyrvy 1201  
fgnvedefwl gldnihrits qgryelrvdm rdgqeaafas ydrfsvedsr nlyklrigsy 1261  
ngtagdlsy hqgrpfsted rdndvavtnc amsykgawwy knchrtlnlg kygesrshsqg 1321  
inwyhwkghe fsipfvemkm rpynhrlmag rkrqslqf

(57) Abstract: The invention provides ligands of ganglioside GD2, including peptide ligands such as GGITNYNSALM; YCG-  
GITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVVCY; GGIANYNTS; YCGGIANYNCY; YCG-  
GIANYNTSCY; and, YCIANYNTCY. GD2 ligands of the invention may for example be used to treat or diagnose diseases such as  
cancers in which cells express GD2, including neuroblastomas.

WO 2004/026895 A2

BEST AVAILABLE COPY



ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- without international search report and to be republished upon receipt of that report

12/pts.

GD2 LIGANDS

10/528542

**FIELD OF THE INVENTION**

The invention includes therapeutic compositions and methods, such as  
5 peptide cancer chemotherapeutic agents.

**BACKGROUND OF THE INVENTION**

Gangliosides are cell surface glycosphingolipids containing one or more  
sialic acid residues. It has been suggested that gangliosides may be localized  
10 within detergent-resistant cell membrane microdomains termed "rafts", which may  
provide the environment for some proteins to function by bringing together adapter  
molecules, modifiers, substrates, or cofactors that would be otherwise too distant or  
too dilute to form complexes and activate a signal cascade. However, little has  
been proposed regarding the possible mechanism of action of gangliosides in  
15 signal transduction.

Ganglioside GD2 is reportedly expressed at low levels in certain neuronal  
populations, but is highly prevalent in many types of tumors (neuroblastoma,  
melanoma, small cell carcinoma of the lung, gliomas, soft tissue sarcomas and B  
20 cell lymphoma).

The extracellular matrix component Tenascin-R was described recently as a  
natural ligand for GD2 (Probstmeier et al., 1999). However, relatively little is known  
about the biological function(s) of GD2 and the functional nature of its interaction  
25 with ligands such as Tenascin-R.


GD2 has been extensively studied as a tumor marker and is used clinically  
as a target for antibody-mediated therapy (e.g. anti-GD2 mAb 3F8) (Cheung et al.,  
1985). However, anti-GD2 mAb 3F8 applied therapeutically to patients causes  
30 acute and transient pain immediately after administration. Anti-GD2 mAb 3F8-  
based therapeutics have been suggested for use in a wide range of cancer

therapeutics and diagnostics, including neuroblastoma and leptomeningeal cancer. For example,  $^{131}\text{I}$ -labeled anti-GD2 3F8 monoclonal antibody has been used in targeted radioimmunotherapy (dosed at 20 mCi/kg) in conjunction with immunotherapy with 400 mg/m<sup>2</sup> unlabeled/unmodified 3F8. Similarly, granulocyte-macrophage colony-stimulating factor (GM-CSF) has been used in conjunction with  
 5 anti-GD2 monoclonal antibody 3F8 in the treatment of patients with neuroblastoma.

## SUMMARY OF THE INVENTION

In one aspect, the invention provides GD2 ligands of Formula I:

10



wherein

15

$\text{X}_1$  is absent or Y or an analogue thereof;

$\text{X}_2$  is absent or C or an analogue thereof;

$\text{X}_3$  is G or Y or an analogue thereof;

$\text{X}_4$  is G or C or Y or an analogue thereof;

$\text{X}_5$  is I or C or an analogue thereof;

$\text{X}_6$  is T or A or an analogue thereof;

20

$\text{X}_7$  is N or an analogue thereof;

$\text{X}_8$  is Y or an analogue thereof;

$\text{X}_9$  is N or G or an analogue thereof;

$\text{X}_{10}$  is S or C or V or T or an analogue thereof;

$\text{X}_{11}$  is A or C or Y or H or S or an analogue thereof;

25

$\text{X}_{12}$  is absent or L or C or Y or an analogue thereof;

$\text{X}_{13}$  is absent or M or Y or an analogue thereof;

$\text{Z}_1$  is an N-terminal group of the formula  $\text{H}_2\text{N}-$ ,  $\text{RHN}-$  or,  $\text{RRN}-$ ;

$\text{Z}_2$  is a C-terminal group of the formula  $-\text{C}(\text{O})\text{OH}$ ,  $-\text{C}(\text{O})\text{R}$ ,  $-\text{C}(\text{O})\text{OR}$ ,  $-\text{C}(\text{O})\text{NHR}$ ,  $-\text{C}(\text{O})\text{NRR}$ ;

30

R at each occurrence is independently selected from  $(\text{C}_1-\text{C}_6)$  alkyl,  $(\text{C}_1-\text{C}_6)$  alkenyl,  $(\text{C}_1-\text{C}_6)$  alkynyl, substituted  $(\text{C}_1-\text{C}_6)$  alkyl, substituted  $(\text{C}_1-\text{C}_6)$  alkenyl, or substituted  $(\text{C}_1-\text{C}_6)$  alkynyl;

and wherein "-" is a covalent linkage.

In alternative embodiments, the invention provides substantially pure synthetic GD2 ligands or recombinant GD2 ligands having a domain of Formula II:

5                   - X<sub>1</sub> - X<sub>2</sub> - X<sub>3</sub> - X<sub>4</sub> - X<sub>5</sub> - X<sub>6</sub> - X<sub>7</sub> - X<sub>8</sub> - X<sub>9</sub> - X<sub>10</sub> - X<sub>11</sub> - X<sub>12</sub> - X<sub>13</sub> - (II)

wherein

X<sub>1</sub> is absent or Y or an analogue thereof;  
X<sub>2</sub> is absent or C or an analogue thereof;  
10       X<sub>3</sub> is G or Y or an analogue thereof;  
X<sub>4</sub> is G or C or Y or an analogue thereof;  
X<sub>5</sub> is I or C or an analogue thereof;  
X<sub>6</sub> is T or A or an analogue thereof;  
X<sub>7</sub> is N or an analogue thereof;  
15       X<sub>8</sub> is Y or an analogue thereof;  
X<sub>9</sub> is N or G or an analogue thereof;  
X<sub>10</sub> is S or C or V or T or an analogue thereof;  
X<sub>11</sub> is A or C or Y or H or S or an analogue thereof;  
X<sub>12</sub> is absent or L or C or Y or an analogue thereof;  
20       X<sub>13</sub> is absent or M or Y or an analogue thereof;  
and wherein "-" is a covalent linkage.

In one aspect, the invention provides recombinant proteins having domains of the invention, wherein the domain is capable of mediating binding of the  
25       recombinant protein to GD2. For example, recombinant T-cell receptors having the domains of the invention may be provided in transformed T-cell lines, such as cytotoxic T-cells (a "cytotoxic T lymphocyte" or "CTL" is an immune system cell that recognises epitopes presented by class I MHC molecules through its TCR.). Transformed T-cell lines of the invention may for example be used to treat diseases  
30       such as cancers having pathological tissues characterized by expression of GD2 (similar to an approach described in United States Patent Application 20020018783

A1, published in the name of Sadelain, M. *et al.* on February 14, 2002, incorporated herein by reference).

The GD2 ligands of the invention may further comprise a cyclic linkage  
5 between any two of X<sub>1</sub> through X<sub>13</sub>. In alternative embodiments, the GD2 ligands of the invention, or the domains of the invention, may be selected from the group consisting of: GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; and, YCIANYNTCY. In some embodiments, known GD2  
10 ligands such as mAb 3F8 and tenascin-R are specifically excluded from the genus of claimed ligands in the present invention. However, in some embodiments, small molecule derivatives and analogs of known ligands (such as small peptides or peptidomimetics of the complementarity determining region of mAbs) are not excluded.

15

The invention also provides methods of treating a subject having a disease wherein disease cells express GD2, the method comprising administering to the subject an effective amount of the GD2 ligands of the invention. Also provided are methods of diagnosis of a disease wherein disease cells express GD2, comprising  
20 determining whether a cell from a subject binds to a GD2 ligand of the invention. The diagnostic and therapeutic methods of the invention may be carried out *in vitro* or *in vivo*.

In alternative embodiments, the GD2 ligands of the invention may be used  
25 with other therapeutic compounds, such as an effective amount of granulocyte-macrophage colony-stimulating factor. The invention provides commercial packages comprising the GD2 ligands of the invention, together with instructions for using the GD2 ligands to modulate GD2 activity or to detect cells expressing GD2.

30 Table 1 sets out the sequences of a number of alternative GD2 ligands or GD2 binding domains of the invention. Structure activity relationship (SAR) and

deletion analysis demonstrate that some substitutions are allowed and that peptide cyclization enhances activity (peptides marked by \* are inactive)

**Table 1: Alternative domains/peptides of the invention**

		G	G	I	T	N	Y	N	S	A	L	M	
Y	C	G	G	I	T	N	Y	N	S	A	C	Y	
		Y	C	I	T	N	Y	N	S	C	Y		
Y	C	G	G	I	T	N	Y	N	C	Y			
			Y	C	T	N	Y	G	V	H	C	Y	*
			Y	C	T	N	Y	G	V	C	Y		*
		G	G	I	A	N	Y	N	T	S			*
Y	C	G	G	I	A	N	Y	N	C	Y			
Y	C	G	G	I	A	N	Y	N	T	S	C	Y	
		Y	C	I	A	N	Y	N	T	C	Y		
X <sub>1</sub>	X <sub>2</sub>	X <sub>3</sub>	X <sub>4</sub>	X <sub>5</sub>	X <sub>6</sub>	X <sub>7</sub>	X <sub>8</sub>	X <sub>9</sub>	X <sub>10</sub>	X <sub>11</sub>	X <sub>12</sub>	X <sub>13</sub>	

5

The invention further provides commercial packages comprising a GD2 ligand, together with instructions for using the GD2 ligand, for example by administering the GD2 ligand to a patient in need of such treatment.

10 In alternative embodiments, the invention provides methods of screening to identify a GD2 ligand. For example, such screening methods may involve:

a) Administering a putative GD2 ligand (such as a polypeptide derived from Tenascin-R) to a system having a GD2 moiety and a p56<sup>Lck</sup> moiety available for association (such as a cell expressing GD2 and p56<sup>Lck</sup>); and,

15 b) Measuring an association between the GD2 and the p56<sup>Lck</sup> moieties in the system, for example by determining a kinase activity of the p56<sup>Lck</sup> moiety. In further alternative embodiments, the invention may include:

c) Measuring an association between the GD2 and the CD45 moieties in the system, for example by determining the phosphatase activity of the

20 CD45 moiety.

In further alternative embodiments, the forgoing method further comprises:

- b) Administering a putative GD2 ligand to a system having a GD2 moiety and a phosphatase such as CD45; and
- c) Measuring an association or functional relationship between GD2 and the phosphatase
- d) A competitive screening assay where test compounds (e.g. a combinatorial library) are used to displace any of the GD2 ligands described herein
- e) A competitive screening assay where any of the GD2 ligands described herein are used to displace test compounds

In some embodiments, the putative GD2 ligand may for example comprise a polypeptide or a non-peptidic analog such as a peptidomimetic that displays the same pharmacophore or has similar side chain functional groups.

## BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1** is the full-length protein sequence of Homo sapiens tenascin-R (restrictin, janusin), from GenBank Accession XP\_040550, with a region identified in bold within a box that is identified in accordance with one aspect of the invention as a GD2 binding region. One aspect of the invention provides alternative tenascin-R proteins in which the GD2 binding region has been altered, for example to modulate the strength of the interaction between GD2 and the tenascin-R protein.

**Figure 2** shows data relating to the co-immunoprecipitation of GD2 and p56<sup>Lck</sup>.

(a) R1.1 and EL4 GD2<sup>positive</sup> cell lysates were subjected to immunoprecipitation with anti-GD2 mAb 3F8 or control mouse IgG (mlg). Presence of p56<sup>Lck</sup> protein in the immunoprecipitates was evaluated by western blotting. p56<sup>Lck</sup> can be immunoprecipitated by mAb 3F8 in EL4 GD2<sup>positive</sup> cells (lane 7) but not in R1.1 cells (lane 5). Total cell lysates were used as a control for p56<sup>Lck</sup> detection (lane 1 and 2).



- (b) and (c) R1.1, EL4 GD2<sup>negative</sup> and EL4 GD2<sup>positive</sup> cell lysates were subjected to immunoprecipitation with anti-GD2 mAb 3F8, GM1-binding cholera toxin B, anti-p56<sup>Lck</sup> mAb 3A5 and anti-Zap-70 mAb LR. Presence of p56<sup>Lck</sup> kinase activity in the immunoprecipitates was evaluated by *in vitro* kinase assay with the p56<sup>Lck</sup>-specific substrates Sam68 and Gap p62. The data in Figure 2 (b) shows that p56<sup>Lck</sup> kinase activity can be immunoprecipitated by mAb 3F8 in EL4 GD2<sup>positive</sup> cells (lane 1) but not in EL4 GD2<sup>negative</sup> cells (lane 4). The data in Figure 2 (c) shows that p56<sup>Lck</sup> kinase activity can be immunoprecipitated by mAb 3F8 in EL4 GD2<sup>positive</sup> cells (lane 1) but by cholera toxin B in R1.1 cells (lane 4).
- (d) R1.1 and EL4 GD2<sup>positive</sup> cell lysates were subjected to immunoprecipitation with anti-GD2 mAb 3F8, GM1-binding cholera toxin B and anti-p56<sup>Lck</sup> mAb 3A5. Presence of gangliosides GD2 and GM1 in the immunoprecipitates was evaluated by ELISA. Anti-p56<sup>Lck</sup> mAb 3A5 can immunoprecipitate GD2 from EL4 GD2<sup>positive</sup> cells, but can not immunoprecipitate GM1 from R1.1 cells. Shown are averages  $\pm$  SEM of one representative experiment. n=4 per experiment.

Figure 3 shows the effect of gangliosides on the *in vitro* kinase activity of purified p56<sup>Lck</sup>. The kinase activity of p56<sup>Lck</sup> was evaluated by measuring the incorporation of <sup>32</sup>PO<sub>4</sub> in a peptidic p56<sup>Lck</sup> substrate over time, with or without GD2 or GM1. Presence of GD2, but not GM1, can positively alter the kinetics of p56<sup>Lck</sup> kinase activity. Activity standardized to untreated p56<sup>Lck</sup> at the 20 minute time point. Shown are averages of 3 to 5 assays  $\pm$  SEM.

Figure 4 shows:

- (a) the effect of GD2 ligands on p56<sup>Lck</sup> phosphorylation. Resting EL4 GD2<sup>positive</sup> cells were treated with mAb 3F8 (13 nM) or control mouse IgG (mlg) for the indicated times. After lysis, p56<sup>Lck</sup> protein was immunoprecipitated with anti-p56<sup>Lck</sup> mAb 3A5 and probed for phosphotyrosine (PY) by western blotting using biotinylated anti-phosphotyrosine mAb 4G10. Anti-GD2 mAb 3F8 can induce tyrosine phosphorylation of p56<sup>Lck</sup> within 5 minutes (lane 3) and sustain it for at least 30 minutes (lane 4).

(b) the effect of GD2 ligands on Zap-70 phosphorylation. Resting EL4 GD2<sup>positive</sup> cells were treated with mAb 3F8 (13 nM) or control mouse IgG (mlg) for the indicated times. After lysis, Zap-70 protein was immunoprecipitated with anti-Zap-70 mAb LR and probed for phosphotyrosine (PY) by western blotting using anti-phosphotyrosine mAb 4G10. Anti-GD2 mAb 3F8 can induce tyrosine phosphorylation of Zap-70 within 5 minutes (lane 3). c) Effect of GD2 ligands on intracellular calcium concentrations. Resting EL4 GD2<sup>positive</sup> cells were treated with mAb 3F8 (13 nM), control mouse IgG (mlg) or the calcium ionophore A23187. Intracellular calcium concentration was evaluated over time by flow cytometry using the calcium-sensitive fluorophore Rhod-2 AM. mAb 3F8 can induce strong, sustainable calcium changes within 5 minutes, while control mouse IgG has no effect. Addition of the p56<sup>Lck</sup> inhibitor PP1 partially abolished mAb 3F8's effects. Shown are averages of 4 independent assays  $\pm$  SEM.

**Figure 5** shows the inhibitory effect of GD2 on *in vitro* CD45 phosphatase activity, particularly when using the pp60<sup>Src</sup> C-terminal phosphoregulatory sequence as a substrate. When co-incubated for 20 minutes, GD2 (but not other gangliosides) can drastically inhibit CD45 phosphatase activity, as measured by the colorimetric quantification of released free phosphate.

**Figure 6** shows the inhibitory effect of GD2 on *ex vivo* CD45 phosphatase activity, measured by the dephosphorylation of tyrosine 505 on p56<sup>Lck</sup>. EL4 GD2<sup>positive</sup> and EL4 GD2<sup>negative</sup> cells were treated with control mlg, anti-GD2 antibody 3F8 or anti-CD3 antibody 145-2C11 cross-linked with anti-hamster antibody G94-56 for 20 minutes at 37°C. After lysis, p56<sup>Lck</sup> was immunoprecipitated with anti-p56<sup>Lck</sup> 3A5 coated beads and probed for phosphotyrosine at position 505 by western blotting with anti-PY505 antibody. EL4 GD2<sup>positive</sup> cells treated with anti-CD3 fail to induce dephosphorylation of p56<sup>Lck</sup> at tyrosine 505 (lane 3), while EL4 GD2<sup>negative</sup> cells show a marked dephosphorylation with the same treatment (lane 6), indicating that the presence of GD2 inhibits the CD45 phosphatase responsible for tyrosine 505 dephosphorylation. GD2 ligands such as anti-GD2 antibody 3F8, are able to relieve CD45 of its GD2-mediated inhibition (lane 2).

**Figure 7** shows data from soft-agar clonogenic assays. EL4 GD2<sup>positive</sup> and EL4 GD2<sup>negative</sup> cells were cultured in soft agar in the presence or absence of anti-GD2 antibody 3F8 (2 plates per sample).

5       **(a)** Total number of visible colonies. EL4 GD2<sup>positive</sup> cells show reduced colony formation compared to EL4 GD2<sup>negative</sup> cells. Anti-GD2 antibody 3F8 abolishes EL4 GD2<sup>positive</sup> cells growth but does not affect EL4 GD2<sup>negative</sup> cells.

**(b)** Typical EL4 GD2<sup>positive</sup> and EL4 GD2<sup>negative</sup> colonies. EL4 GD2<sup>negative</sup> colonies contain many more cells than EL4 GD2<sup>positive</sup> colonies. Bar = 100  
10   micrometers.

**Figure 8** shows data from tumorigenic assays. EL4 GD2<sup>positive</sup> and EL4 GD2<sup>negative</sup> cells were injected intraperitoneally in a) nude Balb/c and b) syngeneic C57BL/g mice. EL4 GD2<sup>negative</sup> injected animals (left) show important ascitic tumors, 15   whereas EL4 GD2<sup>positive</sup> injected animals (right) show localized solid tumors (circled area). Bar = 1 mm.

## 20       **DETAILED DESCRIPTION OF THE INVENTION**

      In one aspect, the invention provides selective artificial ligands of GD2. In some embodiments, such ligands may be used to modulate ganglioside GD2 signal transduction selectively in the tissue where it is normally expressed, particularly in pathways that can be linked to tumorigenic growth or to nociceptive receptors. One aspect of the invention involves the identification of primary and tertiary structures 25   in Tenascin-R that are critical for GD2 binding. In an alternative aspect, the invention demonstrates that a complementarity determining region of anti-GD2 mAb 3F8 is an analogue of Tenascin-R. Small peptide mimics of Tenascin-R and mimics of anti-GD2 mAb 3F8 have accordingly been designed and synthesized as selective ligands of GD2. Alternative ligands may be provided, based on the ligands 30   of the invention, by protein mimicry and antibody mimicry techniques (Saragovi et al., 1992).

In an alternative aspect of the invention, it is demonstrated that GD2 (but not GM1) associates physically with p56<sup>Lck</sup> *in vivo*, in complexes that are stable to detergent lysis. It is shown that GD2 regulates signal transduction by enhancing p56<sup>Lck</sup> enzymatic activity *in vitro* and by enhancing *in vivo* phosphorylation of p56<sup>Lck</sup> and the p56<sup>Lck</sup> substrate Zap70. Accordingly, GD2 ligands of the invention may be used to cause p56<sup>Lck</sup>-dependent fluxes in intracellular calcium in live cells, and thereby to modulate a variety of physiological or pathological cellular functions.

In an alternative aspect of the invention, it is demonstrated that GD2 (but not other gangliosides) can inhibit CD45 phosphatase activity *in vitro* and *ex vivo*. Accordingly, GD2 ligands of the invention may be used to antagonize the inhibitory action of GD2 on CD45 in live cells, and thereby to modulate a variety of physiological, immunological or pathological cellular functions.

In one aspect of the invention, expression of GD2 is shown to alter tumorigenicity *in vitro* and *in vivo*. As shown in the Examples, in EL4 clones that are otherwise phenotypically indistinguishable GD2<sup>negative</sup> than in GD2<sup>positive</sup> cells have equal doubling times, but soft agar colony growth is significantly more efficient in GD2<sup>negative</sup> cells. Further, addition of GD2 ligands in this assay causes the apoptotic death of GD2<sup>positive</sup> cells. GD2<sup>negative</sup> cells are also more tumorigenic *in vivo*. GD2<sup>positive</sup> cells injected intraperitoneally or subcutaneously in syngeneic mice only form solid tumors at the primary site, with little metastasis. In contrast, GD2<sup>negative</sup> cells can digest the peritoneal membrane, form viscous, mucin-like ascitic tumors, small solid tumor nodules, and are highly metastatic. Accordingly, in one aspect of the invention cells may be transformed so that they are GD2<sup>positive</sup>, and the transformed GD2<sup>positive</sup> cells may be treated to GD2 ligands of the invention to mediate cell death, for example by an apoptotic pathway. For example, GD2<sup>negative</sup> cancer cells may be transformed by targeted gene therapy techniques, so that the cells become GD2<sup>positive</sup>, and the transformed GD2<sup>positive</sup> cancer cells may be treated with a GD2 ligand of the invention.

In alternative aspects, GD2 ligands of the invention may be used to influence or modulate signal transduction in a biologically relevant manner *in vitro* and *in vivo* in the treatment of diseases such as cancer and in managing symptoms such as pain .

5

In one aspect, the invention provides compounds, such as GD2 ligands, that are purified, isolated or substantially pure. A compound is "substantially pure" when it is separated from the components that naturally accompany it. Typically, a compound is substantially pure when it is at least 60%, more generally 75% or over 10 90%, by weight, of the total material in a sample. Thus, for example, a polypeptide that is chemically synthesised or produced by recombinant technology will generally be substantially free from its naturally associated components. A nucleic acid molecule is substantially pure when it is not immediately contiguous with (i.e., covalently linked to) the coding sequences with which it is normally contiguous in 15 the naturally occurring genome of the organism from which the DNA of the invention is derived. A substantially pure compound can be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid molecule encoding a polypeptide compound; or by chemical synthesis. Purity can be measured using any appropriate method such as column chromatography, gel 20 electrophoresis, HPLC, etc.

The term "alkyl" refers to the radical of saturated aliphatic groups, including straight chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. 25 Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *t*-butyl, pentyl, isopentyl, hexyl, etc. The alkyl groups can be (C<sub>1</sub>-C<sub>6</sub>) alkyl, or (C<sub>1</sub>-C<sub>3</sub>) alkyl. A "substituted alkyl" has substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, halogen, hydroxyl, carbonyl (such as carboxyl, ketones 30 (including alkylcarbonyl and arylcarbonyl groups), and esters (including alkyloxy carbonyl and aryloxy carbonyl groups)), thiocarbonyl, acyloxy, alkoxyl, phosphoryl, phosphonate, phosphinate, amino, acylamino, amido, amidine, imino,

cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, heterocyclyl, aralkyl, or an aromatic or heteroaromatic moiety. The moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. For instance, the substituents of a substituted alkyl may include substituted and  
5 unsubstituted forms of aminos, azidos, iminos, amidos, phosphoryls (including phosphonates and phosphinates), sulfonyls (including sulfates, sulfonamidos, sulfamoyls and sulfonates), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), -CF<sub>3</sub>, -CN and the like. Exemplary substituted alkyls are described below. Cycloalkyls can be further  
10 substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted alkyls, -CF<sub>3</sub>, -CN, and the like.

The terms "alkenyl" and "alkynyl" refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that  
15 contain at least one double or triple bond respectively. An "alkenyl" is an unsaturated branched, straight chain, or cyclic hydrocarbon radical with at least one carbon-carbon double bond. The radical can be in either the *cis* or *trans* conformation about the double bond(s). Typical alkenyl groups include, but are not limited to, ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, *tert*-butenyl, pentenyl,  
20 hexenyl, etc. An "alkynyl" is an unsaturated branched, straight chain, or cyclic hydrocarbon radical with at least one carbon-carbon triple bond. Typical alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, isobutynyl, pentynyl, hexynyl, etc.

25 A "substantially identical" sequence is an amino acid or nucleotide sequence that differs from a reference sequence only by one or more conservative substitutions, as discussed herein, or by one or more non-conservative substitutions, deletion, or insertions located at positions of the sequence that do not destroy the biological function of the test compound. Such a sequence can be at  
30 least 60% or 75%, or more generally at least 80%, 85%, 90%, or 95%, or as much as 99% identical at the amino acid or nucleotide level to the sequence used for comparison. Sequence identity can be readily measured using publicly available sequence analysis software (e.g., Sequence Analysis Software Package of the

Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, or BLAST software available from the National Library of Medicine). Examples of useful software include the programs, Pile-up and PrettyBox. Such software matches similar sequences by assigning  
5 degrees of homology to various substitutions, deletions, substitutions, and other modifications.

In alternative embodiments, GD2 ligands can be produced by substitution of either/or (i) side chains, (ii) backbone, or (iii) ionic interaction within a peptide.  
10 Additionally, structural or functional analogs can include 1) homologs of the peptidic GD2 ligands generated by peptidomimicry and 2) analogs where the sequence/structure of the GD2 ligands is introduced in a larger protein to convey GD2 binding to that protein.

15 In one aspect the invention provides nucleic acids that encode peptide compounds of the invention. Such nucleic acids may be introduced into cells for expression using standard recombinant techniques for stable or transient expression. Nucleic acid molecules of the invention may include any chain of two or more nucleotides including naturally occurring or non-naturally occurring  
20 nucleotides or nucleotide analogues.

Various genes and nucleic acid sequences of the invention may be recombinant sequences. The term "recombinant" means that something has been recombined, so that when made in reference to a nucleic acid construct the term  
25 refers to a molecule that is comprised of nucleic acid sequences that are joined together or produced by means of molecular biological techniques. The term "recombinant" when made in reference to a protein or a polypeptide refers to a protein or polypeptide molecule which is expressed using a recombinant nucleic acid construct created by means of molecular biological techniques. The term  
30 "recombinant" when made in reference to genetic composition refers to a gamete or progeny or cell or genome with new combinations of alleles that did not occur in the parental genomes. Recombinant nucleic acid constructs may include a nucleotide sequence which is ligated to, or is manipulated to become ligated to, a nucleic acid

sequence to which it is not ligated in nature, or to which it is ligated at a different location in nature. Referring to a nucleic acid construct as 'recombinant' therefore indicates that the nucleic acid molecule has been manipulated using genetic engineering, i.e. by human intervention. Recombinant nucleic acid constructs may  
5 for example be introduced into a host cell by transformation. Such recombinant nucleic acid constructs may include sequences derived from the same host cell species or from different host cell species, which have been isolated and reintroduced into cells of the host species. Recombinant nucleic acid construct sequences may become integrated into a host cell genome, either as a result of the  
10 original transformation of the host cells, or as the result of subsequent recombination and/or repair events.

In one aspect the invention provides antibodies that recognize compounds of the invention, and anti-idiotypic antibodies that in turn recognize such antibodies.  
15 The compounds of the invention can be used to prepare antibodies to GD2 ligands using standard techniques of preparation as, for example, described in Harlow and Lane (Antibodies; A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1988), or known to those skilled in the art. Antibodies can be tailored to minimise adverse host immune response by, for example, using chimeric  
20 antibodies contain an antigen binding domain from one species and the Fc portion from another species, or by using antibodies made from hybridomas of the appropriate species.

Compounds of the invention can be prepared, for example, by replacing,  
25 deleting, or inserting an amino acid residue of a GD2 ligand or domain of the invention, with other conserved amino acid residues, i.e., residues having similar physical, biological, or chemical properties, and screening for biological function. It is well known in the art that some modifications and changes can be made in the structure of a polypeptide without substantially altering the biological  
30 function of that peptide, to obtain a biologically equivalent polypeptide. The peptides, ligands and domains of the present invention also extend to biologically equivalent peptides, ligands and domains that differ from a portion of the sequence



of novel ligands of the present invention by conservative amino acid substitutions. As used herein, the term "conserved amino acid substitutions" refers to the substitution of one amino acid for another at a given location in the peptide, where the substitution can be made without substantial loss of the relevant function. In making such changes, substitutions of like amino acid residues can be made on the basis of relative similarity of side-chain substituents, for example, their size, charge, hydrophobicity, hydrophilicity, and the like, and such substitutions may be assayed for their effect on the function of the peptide by routine testing.

In some embodiments, conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydrophilicity value (e.g., within a value of plus or minus 2.0), where the following may be an amino acid having a hydrophobic index of about -1.6 such as Tyr (-1.3) or Pro (-1.6)s are assigned to amino acid residues (as detailed in United States Patent No. 4,554,101, incorporated herein by reference): Arg (+3.0); Lys (+3.0); Asp (+3.0); Glu (+3.0); Ser (+0.3); Asn (+0.2); Gln (+0.2); Gly (0); Pro (-0.5); Thr (-0.4); Ala (-0.5); His (-0.5); Cys (-1.0); Met (-1.3); Val (-1.5); Leu (-1.8); Ile (-1.8); Tyr (-2.3); Phe (-2.5); and Trp (-3.4).

In alternative embodiments, conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydrophobic index (e.g., within a value of plus or minus 2.0). In such embodiments, each amino acid residue may be assigned a hydrophobic index on the basis of its hydrophobicity and charge characteristics, as follows: Ile (+4.5); Val (+4.2); Leu (+3.8); Phe (+2.8); Cys (+2.5); Met (+1.9); Ala (+1.8); Gly (-0.4); Thr (-0.7); Ser (-0.8); Trp (-0.9); Tyr (-1.3); Pro (-1.6); His (-3.2); Glu (-3.5); Gln (-3.5); Asp (-3.5); Asn (-3.5); Lys (-3.9); and Arg (-4.5).

In alternative embodiments, conserved amino acid substitutions may be made where an amino acid residue is substituted for another in the same class, where the amino acids are divided into non-polar, acidic, basic and neutral classes,

as follows: non-polar: Ala, Val, Leu, Ile, Phe, Trp, Pro, Met; acidic: Asp, Glu; basic: Lys, Arg, His; neutral: Gly, Ser, Thr, Cys, Asn, Gln, Tyr.

Conservative amino acid changes can include the substitution of an L-amino  
5 acid by the corresponding D-amino acid, by a conservative D-amino acid, or by a  
naturally-occurring, non-genetically encoded form of amino acid, as well as a  
conservative substitution of an L-amino acid. Naturally-occurring non-genetically  
encoded amino acids include beta-alanine, 3-amino-propionic acid, 2,3-diamino  
propionic acid, alpha-aminoisobutyric acid, 4-amino-butyric acid, N-methylglycine  
10 (sarcosine), hydroxyproline, ornithine, citrulline, t-butylalanine, t-butylglycine, N-  
methylisoleucine, phenylglycine, cyclohexylalanine, norleucine, norvaline, 2-  
naphthylalanine, pyridylalanine, 3-benzothienyl alanine, 4-chlorophenylalanine, 2-  
fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, penicillamine,  
1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid, beta-2-thienylalanine, methionine  
15 sulfoxide, homoarginine, N-acetyl lysine, 2-amino butyric acid, 2-amino butyric acid,  
2,4,-diamino butyric acid, p-aminophenylalanine, N-methylvaline, homocysteine,  
homoserine, cysteic acid, epsilon-amino hexanoic acid, delta-amino valeric acid, or  
2,3-diaminobutyric acid.

20 In alternative embodiments, conservative amino acid changes include  
changes based on considerations of hydrophilicity or hydrophobicity, size or  
volume, or charge. Amino acids can be generally characterized as hydrophobic or  
hydrophilic, depending primarily on the properties of the amino acid side chain. A  
hydrophobic amino acid exhibits a hydrophobicity of greater than zero, and a  
25 hydrophilic amino acid exhibits a hydrophilicity of less than zero, based on the  
normalized consensus hydrophobicity scale of Eisenberg *et al.* (*J. Mol. Bio.*  
179:125-142, 1984). Genetically encoded hydrophobic amino acids include Gly,  
Ala, Phe, Val, Leu, Ile, Pro, Met and Trp, and genetically encoded hydrophilic  
amino acids include Thr, His, Glu, Gln, Asp, Arg, Ser, and Lys. Non-genetically  
30 encoded hydrophobic amino acids include t-butylalanine, while non-genetically  
encoded hydrophilic amino acids include citrulline and homocysteine.

Hydrophobic or hydrophilic amino acids can be further subdivided based on the characteristics of their side chains. For example, an aromatic amino acid is a hydrophobic amino acid with a side chain containing at least one aromatic or heteroaromatic ring, which may contain one or more substituents such as -OH, -SH, -CN, -F, -Cl, -Br, -I, -NO<sub>2</sub>, -NO, -NH<sub>2</sub>, -NHR, -NRR, -C(O)R, -C(O)OH, -C(O)OR, -C(O)NH<sub>2</sub>, -C(O)NHR, -C(O)NRR, etc., where R is independently (C<sub>1</sub>-C<sub>6</sub>) alkyl, substituted (C<sub>1</sub>-C<sub>6</sub>) alkyl, (C<sub>1</sub>-C<sub>6</sub>) alkenyl, substituted (C<sub>1</sub>-C<sub>6</sub>) alkenyl, (C<sub>1</sub>-C<sub>6</sub>) alkynyl, substituted (C<sub>1</sub>-C<sub>6</sub>) alkynyl, (C<sub>5</sub>-C<sub>20</sub>) aryl, substituted (C<sub>5</sub>-C<sub>20</sub>) aryl, (C<sub>6</sub>-C<sub>26</sub>) alkaryl, substituted (C<sub>6</sub>-C<sub>26</sub>) alkaryl, 5-20 membered heteroaryl, substituted 5-20 membered heteroaryl, 6-26 membered alkheteroaryl or substituted 6-26 membered alkheteroaryl. Genetically encoded aromatic amino acids include Phe, Tyr, and Trp, while non-genetically encoded aromatic amino acids include phenylglycine, 2-naphthylalanine, beta-2-thienylalanine, 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, and 4-fluorophenylalanine.

An apolar amino acid is a hydrophobic amino acid with a side chain that is uncharged at physiological pH and which has bonds in which a pair of electrons shared in common by two atoms is generally held equally by each of the two atoms (i.e., the side chain is not polar). Genetically encoded apolar amino acids include Gly, Leu, Val, Ile, Ala, and Met, while non-genetically encoded apolar amino acids include cyclohexylalanine. Apolar amino acids can be further subdivided to include aliphatic amino acids, which is a hydrophobic amino acid having an aliphatic hydrocarbon side chain. Genetically encoded aliphatic amino acids include Ala, Leu, Val, and Ile, while non-genetically encoded aliphatic amino acids include norleucine.

A polar amino acid is a hydrophilic amino acid with a side chain that is uncharged at physiological pH, but which has one bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms. Genetically encoded polar amino acids include Ser, Thr, Asn, and Gln,

while non-genetically encoded polar amino acids include citrulline, N-acetyl lysine, and methionine sulfoxide.

5 An acidic amino acid is a hydrophilic amino acid with a side chain pKa value of less than 7. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Genetically encoded acidic amino acids include Asp and Glu. A basic amino acid is a hydrophilic amino acid with a side chain pKa value of greater than 7. Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion.

10 Genetically encoded basic amino acids include Arg, Lys, and His, while non-genetically encoded basic amino acids include the non-cyclic amino acids ornithine, 2,3,-diaminopropionic acid, 2,4-diaminobutyric acid, and homoarginine.

The above classifications are not absolute and an amino acid may be

15 classified in more than one category. In addition, amino acids can be classified based on known behaviour and or characteristic chemical, physical, or biological properties based on specified assays or as compared with previously identified amino acids. Amino acids can also include bifunctional moieties having amino acid-like side chains.

20

Conservative changes can also include the substitution of a chemically derivatised moiety for a non-derivatised residue, by for example, reaction of a functional side group of an amino acid. Thus, these substitutions can include compounds whose free amino groups have been derivatised to amine

25 hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Similarly, free carboxyl groups can be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides, and side chains can be derivatized to form O-acyl or O-alkyl derivatives for free hydroxyl groups or N-im-benzylhistidine for the imidazole nitrogen of

30 histidine. Peptide analogues also include amino acids that have been chemically altered, for example, by methylation, by amidation of the C-terminal amino acid by an alkylamine such as ethylamine, ethanolamine, or ethylene diamine, or acylation

or methylation of an amino acid side chain (such as acylation of the epsilon amino group of lysine). Peptide analogues can also include replacement of the amide linkage in the peptide with a substituted amide (for example, groups of the formula  $-C(O)-NR$ , where R is  $(C_1-C_6)$  alkyl,  $(C_1-C_6)$  alkenyl,  $(C_1-C_6)$  alkynyl, substituted  $(C_1-C_6)$  alkyl, substituted  $(C_1-C_6)$  alkenyl, or substituted  $(C_1-C_6)$  alkynyl) or isostere of an amide linkage (for example,  $-CH_2NH-$ ,  $-CH_2S-$ ,  $-CH_2CH_2-$ ,  $-CH=CH-$  (cis and trans),  $-C(O)CH_2-$ ,  $-CH(OH)CH_2-$ , or  $-CH_2SO-$ ).

The GD2 ligands, peptides and domains of the invention may be covalently linked, for example, by polymerisation or conjugation, to form homopolymers or heteropolymers. Spacers and linkers, typically composed of small neutral molecules, such as amino acids that are uncharged under physiological conditions, can be used. Linkages can be achieved in a number of ways. For example, cysteine residues can be added at the peptide termini, and multiple peptides can be covalently bonded by controlled oxidation. Alternatively, heterobifunctional agents, such as disulfide/amide forming agents or thioether/amide forming agents can be used. The compound can also be linked to a lipid-containing molecule or peptide that can enhance a T cell response. The compound can also be constrained, for example, by having cyclic portions.

20

Peptides or peptide analogues can be synthesised by standard chemical techniques, for example, by automated synthesis using solution or solid phase synthesis methodology. Automated peptide synthesisers are commercially available and use techniques well known in the art. Peptides and peptide analogues can also be prepared using recombinant DNA technology using standard methods.

Compounds of the invention can be provided alone or in combination or conjugation with other compounds (for example, toxins, growth factors, anti-apoptotic agents, small molecules, peptides, or peptide analogues), in the presence of a liposome, an adjuvant, or any pharmaceutically acceptable carrier, in a form suitable for administration to humans. Conventional pharmaceutical practice may

30

be employed to provide suitable formulations or compositions to administer the compounds to patients suffering from diseases such as cancer. Any appropriate route of administration may be employed, for example, parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, or oral administration. Therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.

10

Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for modulatory compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

15  
20

If desired, treatment with a compound according to the invention may be combined with more traditional therapies for the disease such as, for example, surgery or chemotherapy.

25

For therapeutic or prophylactic compositions, the compounds may be administered to an individual in an amount sufficient to induce the destruction of cells (such as cancer cells) or to stop or slow the destruction of cells (such as in neuroprotective treatments or treatment of pain). Amounts considered sufficient will vary according to the specific compound used, the mode of administration, the stage and severity of the disease, the age, sex, and health of the individual being

30

treated, and concurrent treatments. As a general rule, however, dosages can range from about 1 microgram to about 100 mg per kg body weight of a patient for an initial dosage, with subsequent adjustments depending on the patient's response.

5

In the case of vaccine formulations, an immunogenically effective amount of a compound of the invention can be provided, alone or in combination with other compounds, with an adjuvant, for example, Freund's incomplete adjuvant or aluminum hydroxide. The compound may also be linked with a carrier molecule, such as bovine serum albumin or keyhole limpet hemocyanin to enhance immunogenicity.

10

In general, compounds of the invention should be used without causing substantial toxicity. Toxicity of the compounds of the invention can be determined using standard techniques, for example, by testing in cell cultures or experimental animals and determining the therapeutic index, i.e., the ratio between the LD50 (the dose lethal to 50% of the population) and the LD100 (the dose lethal to 100% of the population). In some circumstances however, such as in severe disease conditions, it may be necessary to administer substantial excesses of the compositions.

15  
20

The following examples are intended to illustrate various embodiments and aspects of the invention, and do not limit the invention in any way.

## 25 **Examples**

## Methods

**Cells:** EL4 murine lymphoma and R1.1 murine lymphoma were grown in RPMI 1640 medium (Life Technologies) supplemented with 5% fetal bovine serum, 2 mM glutamine, 10 mM Hepes and penicillin/streptomycin at 37°C in 5% CO<sub>2</sub> humidified atmosphere. A GD2-negative mutant of EL4 was obtained after subcloning of EL4 cells resistant to culture with anti-GD2 mAb 3F8 and rabbit complement.

**Flow cytometry:** 10<sup>5</sup> cells in 50 µl FACS buffer (PBS, 0.5% BSA, 0.05% NaN<sub>3</sub>) were stained for 30 minutes on ice with the following ligands: for GD2, fluorescein isothiocyanate (FITC)-conjugated anti-GD2 mAb 3F8; for GM1, FITC-conjugated cholera toxin B subunit (Sigma); for GM2, rabbit anti-GM2 mAb NANA (Matreya) followed by FITC-conjugated anti-rabbit antibody (Sigma); for GD3, mouse anti-GD3 mAb (Pharmingen) followed by FITC conjugated anti-mouse antibody (Sigma). Cells were washed twice with FACS buffer and analyzed on a flow cytometer (Becton-Dickinson) using CellQuest software.

**Detection of GD2 or GM1 by ELISA:** 12.5 ng/well of ganglioside (GD2, Advanced Immunochemicals or GM1) were immobilized by drying onto PVC 96-well plates (Falcon), followed by blocking with PBS-0.5% BSA for one hour. Then, anti-GD2 mAb 3F8 or biotin-CTB were added for 10 minutes. The plate was washed three times with PBS-0.5% BSA and incubated 60 minutes with horseradish peroxidase (HRP)-conjugated anti-mouse antibody or HRP-conjugated-avidin. After three washes with PBS-0.5% BSA and two with PBS, the colorimetric substrate ABTS was added and the plate read at 414 nm on a Biorad 550 plate reader.

**Co-immunoprecipitation of GD2 and p56<sup>Lck</sup>:** cells (5 x 10<sup>6</sup> per sample) were washed in PBS, resuspended in 1 ml lysis buffer (150 mM NaCl, 10 mM sodium phosphate pH 7.2, 2 mM EDTA, 50 mM NaF, 1% CHAPS, 200 µM sodium orthovanadate, 1 mM PMSF, 100 µM leupeptin, 1 mM benzamidine, 300 nM aprotinin, 500 nM soybean trypsin inhibitor) and incubated 30 minutes at 4°C.



Supernatants were collected from lysates after centrifugation (16000 g for 15 minutes at 4°C). Immunoprecipitations were carried out overnight at 4°C using 50 µl protein-G sepharose (Sigma) with either 5 µg of anti-GD2 mAb 3F8 or anti-p56<sup>Lck</sup> mAb 3A5 (Santa Cruz Biotechnology) or control IgG; or with 50 µl avidin-agarose (Sigma) and 5 µg of biotin-CTB which is specific for GM1 gangliosides.

Immunoprecipitates were washed 5 times with 1 ml of cold lysis buffer containing decreasing concentration of CHAPS detergent and samples were extracted with reduced Laemmli buffer. Samples were then used for western blot analysis (see below), or lipids from the samples were isolated for ganglioside quantification by ELISA (see above).

**Biochemical analysis: Western blotting:** the immunoprecipitated samples were fractionated in SDS-PAGE and transferred to membranes, p56<sup>Lck</sup> immunoblotting was done using rabbit polyclonal anti-p56<sup>Lck</sup> antibody. *Tyrosine phosphorylation of p56<sup>Lck</sup> and Zap70:* cells (5 x 10<sup>6</sup> per sample) were washed with PBS, resuspended in 5 ml protein-free hybridoma medium containing 0.2% BSA and allowed to rest for 60 minutes at 37°C to lower baseline kinase activity. Then, 10 µg Anti-GD2 mAb 3F8 (13 nM concentration) or non-specific mouse IgG were added for 5 and 20 minutes. Samples were then washed in cold PBS, detergent solubilized in lysis buffer and immunoprecipitated using 5 µg of anti-p56<sup>Lck</sup> mAb 3A5 (Santa Cruz Biotechnology) or anti-Zap70 mAb LR (Santa Cruz Biotechnology). Samples were then analyzed by western blotting using anti-phosphotyrosine mAb 4G10. *In vitro p56<sup>Lck</sup> kinase activity:* p56<sup>Lck</sup> immunoprecipitates were incubated for 20 minutes at 37°C with p56<sup>Lck</sup>-specific substrates GAP p62 or Sam68 in a kinase reaction buffer (10 mM MnCl<sub>2</sub>, 20 mM Tris-HCl pH 7.4, 2.5 µM ATP, 20 µCi [ $\gamma$ -<sup>32</sup>P]ATP). The reaction was stopped by addition of reduced Laemmli buffer and boiling. Phosphorylation of p56<sup>Lck</sup> substrates was visualized and quantified by SDS-PAGE followed by analysis on a Storm 840 phosphorimager with ImageQuant software.

30

**Effect of exogenous GD2 on p56<sup>Lck</sup> *in vitro* kinase assay:**  
chromatographically purified p56<sup>Lck</sup> tyrosine kinase (Upstate Biotechnology) was

incubated on ice for 10 minutes in kinase buffer (100 mM Tris-HCl, pH 7.2, 125 mM MgCl<sub>2</sub>, 25 mM MnCl<sub>2</sub>, 2mM EGTA, 150 μM ATP, 0.25 mM sodium orthovanadate, 2 mM DTT) with or without ~20 fold molar excess of ganglioside and 10 μCi [ $\gamma$ -<sup>32</sup>P]ATP. Then 10 μg of the Src kinase substrate peptide p34<sup>cdc2</sup>(6-20) (Upstate  
5 Biothechnology) was added to the mix and incubated at room temperature for the times indicated, after which the reaction was stopped by addition of 100 μM iodoacetamide and by precipitation of proteins with final 10% TCA. The supernatant (containing the phosphorylated peptide substrate, not precipitated by TCA) was spotted on a P81 paper (Whatman) and washed three times with 0.75% phosphoric  
10 acid and once with acetone. The [<sup>32</sup>P]-peptide content was quantified using a Storm 840 phosphorimager with ImageQuant software.

**GD2 ligand design and synthesis:** Peptides were modeled based on Tenascin-R sequence and on diversity within Tenascin family homologs. Peptides  
15 were synthesized with an Advanced Chemtech automatic synthesizer using solid-phase Fmoc chemistry. After cleavage from resin and side-chain deprotection, peptides containing terminal cysteines were subjected to cyclization by oxydation at 4°C under O<sub>2</sub> in 50 mM ammonium bicarbonate, pH 8.5. Peptides were purified (>95%) by HPLC (Varian) using a C-18 preparative column (Phenomenex), and  
20 were verified by Mass Spectrometry.

**Assessment of peptide-GD2 interaction by competitive ELISA:** ELISAs were as described above, except that peptides (50 μg/well, in PBS) were added to the wells for 1 hour before anti-GD2 mAb 3F8 or anti-GM1 cholera toxin-B.  
25 Selectivity of inhibition is controlled by lack of effect upon GM1-CTB interactions.

**Intracellular calcium studies:** cells (1 x 10<sup>6</sup> per sample) were washed with Ringer's solution (155 mM NaCl, 4.5 mM KCl, 2 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM D-glucose, 5 mM HEPES) and resuspended in 1 ml Ringer's containing 10 μM p56<sup>Lck</sup>  
30 inhibitor PP1 (BioMol) or vehicle for 15 minutes at 37°C. Then 5 μM Rhod-2AM (Molecular Probes) was then added to the cells and incubated for 30 minutes at room temprature with mild agitation. Cells were washed once in Ringer's,

resuspended in 1 ml Ringer's and incubated for 30 minutes, after which cells were stimulated with the indicated ganglioside ligands (or calcium ionophore A23187 as control) and analyzed over a 30 minute period for intracellular  $\text{Ca}^{2+}$  using a flow cytometer (Becton-Dickinson).

5

**Soft agar colony formation:** single cell suspensions of EL4 GD2<sup>negative</sup> and EL4 GD2<sup>positive</sup> were plated (1500 cells/plate) with or without mAb 3F8 ( 50  $\mu\text{g}/\text{plate}$ ) in top layer medium (RPMI 1640 containing 0.35% agar, 15% fetal bovine serum, 2 mM glutamine, 10 mM Hepes and penicillin/streptomycin) on top of a preformed bottom layer (same as above except 0.5% agar) in 100 mm polystyrene dishes (Falcon) and grown until colonies are visible by eye. Colonies were counted in a predetermined area of the plates.

**In vivo tumor studies:** single cell suspensions of EL4 GD2<sup>negative</sup> and EL4 GD2<sup>positive</sup> in Hanks' balanced salt solution (Gibco) were injected intraperitoneally in nude Balb/c mice (Charles River) ( $1 \times 10^6$  cells per animal). Animals were sacrificed and autopsied after 7 to 10 days, depending on tumor growth.

**In vitro CD45 phosphatase assay:** human recombinant CD45 enzyme (BioMol, 75 units/well) was preincubated in the absence (negative control) or presence of sodium orthovanadate (positive control) or various gangliosides (16.7  $\mu\text{M}$ ) for 20 minutes at room temperature in half-volume 96-well microtiter plates. A CD45-specific substrate (pp60<sup>Src</sup> C-terminal phosphoregulatory peptide, 200  $\mu\text{M}$ ) was then added for 20 minutes at 30°C, after which the reaction was stopped and quantified with BioMol Green reagent. Plates were read at 620 nm with a Biorad 550 plate reader.

**Ex vivo CD45 assay:** single cell suspensions of EL4 GD2<sup>negative</sup> and EL4 GD2<sup>positive</sup> ( $1 \times 10^7$  cells/ml per treatment) were incubated in the presence of 5  $\mu\text{g}/\text{ml}$  of mlg (negative control), anti-GD2 antibody 3F8 or anti-CD3 antibody 145-2C11 (Pharmingen) cross-linked with anti-hamster G94-56 (Pharmingen) for 20 minutes at 37°C in RPMI 1640 medium supplemented with 5% fetal bovine serum,

2 mM glutamine, 10 mM Hepes and penicillin/streptomycin. Cells were then washed and detergent lysed. p56<sup>Lck</sup> was then immunoprecipitated with anti-p56<sup>Lck</sup> antibody coated beads and probed for phosphotyrosine 505 by western blotting with anti-PY505 (Cell Signaling Technology).

5

## Results

To study a specific physical association between p56<sup>Lck</sup> and gangliosides, a panel of cells was generated varying in expression of cell surface GD2, GM1, GM2 and GD3, as assessed by flow cytometry. The indicated cells (Table 2) express similar levels of p56<sup>Lck</sup> (data not shown).

10

**Table 2 Surface ganglioside expression of cells studied as assessed by FACSscan**

Cells	Source	Ganglioside profile				p56 <sup>Lck</sup> expression
		GM1	GD2	GD3	GM2	
EL4 GD2 <sup>positive</sup>	lymphoma mouse C57/bl6n	Low	high	negative	negative	High
EL4 GD2 <sup>negative</sup>	lymphoma mouse C57/bl6n	Low	negative	medium	negative	High
R1.1	lymphoma mouse C58/J	High	low	negative	negative	High

### 15 Specific and stable association of p56<sup>Lck</sup>-GD2.

We performed anti-GD2 immunoprecipitations with mAb 3F8 followed by western blotting with anti-p56<sup>Lck</sup> antibodies (Figure 2A). In EL4 GD2<sup>positive</sup> cells p56<sup>Lck</sup> was co-precipitated with mAb 3F8 but not with control mouse IgG. In control R1.1 cells, which are GD2<sup>negative</sup>, no antibody co-precipitated p56<sup>Lck</sup>, although p56<sup>Lck</sup> is expressed at high levels.

20

The presence and kinase activity of p56<sup>Lck</sup> in anti-GD2 immunoprecipitates were verified and quantified (Figures 2B and 2C). The indicated immunoprecipitations were done on EL4 GD2<sup>positive</sup> or EL4 GD2<sup>negative</sup> cells, followed by *in vitro* kinase assays using the specific p56<sup>Lck</sup> substrate Sam68. In EL4 GD2<sup>positive</sup> approximately 15% of the p56<sup>Lck</sup> activity was co-precipitated by anti-GD2 mAb 3F8 (Figure 2B, lane 1), compared with anti-Lck mAb 3A5 (Figure 2B, lane 2).

25

In fact, anti-GD2 co-precipitation of the p56<sup>Lck</sup> activity was comparable to co-precipitation by antibodies against Zap70 (Figure 2B, lane 3). This was in keeping with the fact that Zap70 and p56<sup>Lck</sup> are reportedly associated physically and functionally *in vivo*.

5

The specificity of these assays is validated in studies using EL4 GD2<sup>negative</sup> cells, where anti-GD2 mAb 3F8 did not co-precipitate a p56<sup>Lck</sup> activity (Figure 2B, lane 4), while anti-Lck and anti-Zap70 antibodies did (Figure 2B, lanes 5 and 6). Because p56<sup>Lck</sup> co-immunoprecipitations with anti-Zap70 antibodies were  
10 comparable in EL4 GD2<sup>positive</sup> and EL4 GD2<sup>negative</sup> cell lines (Figure 2B, lanes 3 and 6), the data suggest that association of Zap70 and p56<sup>Lck</sup> can be GD2 independent.

Similar studies were done using EL4 GD2<sup>positive</sup> or R1.1 (GD2<sup>negative</sup>) cells and assaying a p56<sup>Lck</sup> activity by *in vitro* kinase activity upon the selective substrate  
15 Gap62 (Figure 2C). Again, anti-GD2 co-purified a p56<sup>Lck</sup> activity that corresponds to ~15% of the activity purified with anti-Lck mAb 3A5. In contrast, affinity isolation of GM1 with cholera toxin b subunit-coupled beads did not co-purify a p56<sup>Lck</sup> activity (Figure 2C, lane 4), although R1.1 cells have high levels of GM1 and p56<sup>Lck</sup> (Figure 2C, lane 3).

20

The converse experiment was performed where p56<sup>Lck</sup> was first immunoprecipitated with mAb 3A5 and then the presence of GD2 or GM1 were gauged by ELISA (Figure 2D). Anti-p56<sup>Lck</sup> immunoprecipitates from EL4 GD2<sup>positive</sup> cells contained ~55% of the GD2 that could be isolated with anti-GD2 mAb 3F8. In  
25 specificity controls, anti-p56<sup>Lck</sup> immunoprecipitates from R1.1 cells did not co-precipitate the ganglioside GM1.

#### **Functional relevance of p56<sup>Lck</sup>-GD2 association in the absence of GD2 ligands.**

30

Subsequent experiments (Figure 3) addressed *in vitro* whether there is a functional relevance to the stable and selective GD2-p56<sup>Lck</sup> association. Addition of exogenous GD2 to purified p56<sup>Lck</sup> increased the kinetics of *in vitro* enzymatic

activity from a  $t_{1/2}$  of ~25 minutes to a  $t_{1/2}$  of ~17 minutes, with a dramatic 70% increase in kinase activity at 20 minutes. However, the  $v_{max}$  did not change, as the enzyme activity reaches a similar plateau with or without GD2 present. In control assays, p56<sup>Lck</sup> kinase activity was not altered upon addition of exogenous GM1  
5 (Figure 3), or addition of phosphatidylcholine or other lipids (data not shown).

#### Development of artificial GD2 ligands.

Small peptides (6-13 amino acids in length) were designed to span the primary sequence of the GD2 ligand Tenascin-R. Cyclization and other  
10 conformational constraints were introduced in these peptides to conformationally constrain them and to force them to adopt the  $\beta$ -turn structures desired.

These peptides (~100 were synthesized) were tested for inhibition of GD2-mAb 3F8 interactions in ELISA plates (Table 3). No competitor peptide added or  
15 control irrelevant peptide added were standardized as 100% binding. For simplicity, only some of the ~90 inactive peptides are shown.

In various embodiments, peptide analogs that actively inhibit GD2-mAb 3F8 interactions span the sequence NH<sub>2</sub>-Ile-Thr(Ala)-Asn-Tyr-Asn-COOH. In some  
20 embodiments, peptides of the invention may be in type IV (3:5 or 3:3) canonical  $\beta$ -turn configurations with a distance between the C $\alpha$ 1 to C $\alpha$ 4 atom varying between 4 and 7 Å, depending on whether Gly residues (underlined) are incorporated in the sequence. Additionally, a *linear* peptide of 11 amino acids (pep 51), which is unstructured in solution (data not shown) can also act as a competitive inhibitor.

25

Table 3. Selected peptide mimics..

Peptides	Sequence	Conformation	% Inhibition of mAb 3F8–GD2 interactions
Pep 51	<u>G</u> G I T N Y N S A L M	linear	44.96 ± 1.57
Pep 52	C <u>G G</u> I T N Y N S A C	cyclic	30.17 ± 2.69
Pep 53	C I T N Y N S C	cyclic	24.74 ± 3.29
Pep 54	C <u>G G</u> I T N Y N C	cyclic	40.34 ± 3.17
Pep 55	C T N Y G V H C	cyclic	12.23 ± 4.41
Pep 56	C T N Y G V C	cyclic	14.13 ± 5.43
Pep 57	G G I A N Y N T S	linear	4.33 ± 5.23
Pep 58	C <u>G G</u> I A N Y N C	cyclic	47.60 ± 4.26
Pep 59	C <u>G G</u> I A N Y N T S C	cyclic	48.83 ± 5.01
Pep 60	C I A N Y N T C	cyclic	30.94 ± 3.53

Inhibition of mAb 3F8 binding to immobilized GD2 by peptides, measured by competitive ELISA. No peptide or control peptide treatments are standardized as 5 0% inhibition. No mAb 3F8 treatment is standardized as 100% inhibition. Average of 5 independent experiments, n=4 in each experiment. Mean ± SEM.

#### Functional relevance of GD2 ligands in p56<sup>Lck</sup> activation.

This example illustrates (i) whether engagement of cell surface GD2 with 10 ligands causes the pTyr of p56<sup>Lck</sup> (Figure 4A); (ii) whether engagement of cell surface GD2 with ligands leads to the pTyr of the downstream effector Zap70 (Figure 4B); (iii) whether engagement of cell surface GD2 induces intracellular calcium fluxes (Figure 4C).

15 First, engagement of cell surface GD2 in living EL4 GD2<sup>positive</sup> cells with the artificial GD2 ligand mAb 3F8 caused the pTyr of p56<sup>Lck</sup> within 5 min *in vivo* (Figure 4A, lanes 3 and 4). Control mouse IgG did not cause this effect (Figure 4A, lanes 1 and 2).

Second, since the pTyr of p56<sup>Lck</sup> can lead either to activation or to inactivation of this kinase depending on which Tyr residue gets phosphorylated, the pTyr profile of Zap70 was studied *in vivo* because it is an adapter molecule downstream of and phosphorylated by activated p56<sup>Lck</sup>. Zap70 is transiently pTyr upon engagement of cell-surface GD2 with mAb 3F8 as a ligand (Figure 4B, lanes 3 and 4). This Zap70 pTyr presumably occurs via p56<sup>Lck</sup>. Control mouse IgG did not cause Zap70 pTyr in EL4 GD2<sup>positive</sup> cells (Figure 4B, lanes 1 and 2). In other specificity controls, treatment of EL4 GD2<sup>negative</sup> cells with GD2 ligands did not cause pTyr of p56<sup>Lck</sup> or Zap70 (data not shown) indicating that cell surface GD2 expression may be required for ligand engagement of GD2 and a subsequent effect downstream, in some embodiments.

Third, intracellular Ca<sup>++</sup> concentrations were measured in live EL4 GD2<sup>positive</sup> cells after engagement of cell-surface GD2 with ligands (Figure 4C). Flow cytometric analysis using the Ca<sup>++</sup> sensitive Rhod-2 fluorophore showed a rapid (~5 minutes) 1.6 fold increase of intracellular Ca<sup>++</sup> after mAb 3F8 binding, but not after binding by control mouse antibody or CTB (data not shown). The selective p56<sup>Lck</sup> kinase inhibitor PP1 (10  $\mu$ M) markedly decreased mAb 3F8-induction of Ca<sup>++</sup> fluxes. This control suggests that activated p56<sup>Lck</sup> may be responsible for aspects of the GD2 signal transduction pathway leading to intracellular Ca<sup>++</sup> fluxes in some embodiments.

#### **Functional relevance of the presence of GD2 on CD45 activity.**

Since the CD45 phosphatase is responsible for the activation of p56<sup>Lck</sup>, the effect of GD2 on CD45 activity was investigated. First, the effect of GD2 was tested *in vitro* using human recombinant CD45 enzyme and pp60<sup>Src</sup> phosphoregulatory peptide as a substrate. As seen in figure 5, GD2 can drastically inhibit CD45 phosphatase activity (85% inhibition), while other gangliosides (GM1, GM2, GD3 and GM3) had little influence on the enzymatic activity of CD45. Other than GD2, only GD1a showed significant inhibition (50%).



The inhibitory effect of GD2 on CD45 is also seen in live cells, as shown in figure 6. Here, EL4 GD2<sup>positive</sup> and EL4 GD2<sup>negative</sup> cells were stimulated using the well-documented T cell receptor cross-linking methodology, which typically results in activation of p56<sup>Lck</sup> following its dephosphorylation at tyrosine 505 by CD45.

5 Interestingly, EL4GD2<sup>positive</sup> cells are resistant to activation (Figure 6, lane 3), while the EL4 GD2<sup>negative</sup> cells (Figure 7, lane 6) are readily activated upon T cell receptor cross-linking. This discrepancy can be attributed to the presence of GD2 in EL4 GD2<sup>positive</sup> cells which can block CD45-mediated activation of p56<sup>Lck</sup>. Of interest is the fact that GD2 ligands, such as mAb 3F8, seem to be able to alleviate GD2

10 inhibition of CD45 and allow for T cell receptor activation as seen by dephosphorylation of tyrosine 505 on p56<sup>Lck</sup> (Figure 6, lane 2).

#### **Functional relevance of GD2 and GD2 ligands in tumorigenic growth.**

To illustrate the effect of cell surface expression of GD2 on cancer cell

15 growth and survival, EL4 GD2<sup>positive</sup> and EL4 GD2<sup>negative</sup> cells were grown in clonoenic (soft agar) assays (Figure 7), or they were injected *in vivo* intraperitoneally (Figure 8).

Colony formation assays in soft agar showed marked differences in growth

20 dynamics for EL4 GD2<sup>positive</sup> and EL4 GD2<sup>negative</sup> cells. At day 10 of growth, the total number of EL4 GD2<sup>positive</sup> colonies per plate were lower by 50% compared to EL4 GD2<sup>negative</sup> colonies (Figure 7a). Moreover the EL4 GD2<sup>negative</sup> colonies were much larger and contained more cells (Figure 7b). This is striking because both cell lines have identical doubling times in liquid culture.

25 Addition of mAb 3F8 in the agar layer (where it putatively diffuses, engages and activates GD2-mediated signals) totally abolished EL4 GD2<sup>positive</sup> colony formation while having no consequences on the number and size of EL4 GD2<sup>negative</sup> colonies. This illustrates that the GD2 ligands of the invention may be used to treat

30 GD2 positive cells to modulate growth, for example to treat cancer cells expressing GD2 to inhibit the growth of such cells or to kill the cells. In some embodiments, EL4 GD2<sup>positive</sup> cells die by apoptosis when GD2 is bound (data not shown),

indicating that the presence of GD2 may in some embodiments allow the GD2 ligands of the invention to be used to induce apoptosis.

5 An evident difference is also observed when cells are grown *in vivo*. When injected intraperitoneally EL4 GD2<sup>negative</sup> cells mainly form aggressive and metastatic ascitic tumors and the peritoneal cavity contains mucin-like peptidoglycans. In contrast, EL4 GD2<sup>positive</sup> cells form localized, highly vascularized solid tumors attached to the peritoneal membrane (Figure 8).

## 10 Conclusion

Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way.

15 Numeric ranges are inclusive of the numbers defining the range. In the specification, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to", and the word "comprises" has a corresponding meaning. Citation of references herein shall not be construed

20 as an admission that such references are prior art to the present invention. All publications, including but not limited to patents and patent applications, cited in this specification are incorporated herein by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein and as though fully set forth herein. The invention includes all

25 embodiments and variations substantially as hereinbefore described and with reference to the examples and drawings.

## References

The following documents are hereby incorporated by reference:

30

Cheung, N. K., Saarinen, U. M., Neely, J. E., Landmeier, B., Donovan, D., and Coccia, P. F. (1985). Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells, *Cancer Research* 45, 2642-9.

- 5 Eisenberg, D., Schwarz, E., Komaromy, M., Wall, R. (1984). Analysis of membrane and surface protein sequences with the hydrophobic moment plot, *Journal of Molecular Biology* 179 , 125-42.

- Gagnon, M., and Saragovi, H. U. (2002). Gangliosides: therapeutic agents or  
10 therapeutic targets?, *Expert Opinion on Therapeutic Patents* 12, 1215-1224.

- Probstmeier, R., Michels, M., Franz, T., Chan, B. M., and Pesheva, P. (1999).  
Tenascin-R interferes with integrin-dependent oligodendrocyte precursor cell  
adhesion by a ganglioside-mediated signalling mechanism, *European Journal of*  
15 *Neuroscience* 11, 2474-88.


- Saragovi, H. U., Greene, M. I., Chrusciel, R. A., and Kahn, M. (1992). Loops and  
secondary structure mimetics: development and applications in basic science and  
rational drug design, *Bio/Technology* 10, 773-8.

- 20 Sorkin, L. S. (2000). Antibody activation and immune reactions: potential linkage to  
pain and neuropathy, *Pain Medicine* 1, 296-302.

25

**WHAT IS CLAIMED IS:**

1. A substantially pure GD2 ligand of Formula I:



wherein

$X_1$  is absent or Y or an analogue thereof;

$X_2$  is absent or C or an analogue thereof;

$X_3$  is G or Y or an analogue thereof;

$X_4$  is G or C or Y or an analogue thereof;

$X_5$  is I or C or an analogue thereof;

$X_6$  is T or A or an analogue thereof;

$X_7$  is N or an analogue thereof;

$X_8$  is Y or an analogue thereof;

$X_9$  is N or G or an analogue thereof;

$X_{10}$  is S or C or V or T or an analogue thereof;

$X_{11}$  is A or C or Y or H or S or an analogue thereof;

$X_{12}$  is absent or L or C or Y or an analogue thereof;


$X_{13}$  is absent or M or Y or an analogue thereof;

$Z_1$  is an N-terminal group of the formula  $H_2N-$ ,  $RHN-$  or,  $RRN-$ ;

$Z_2$  is a C-terminal group of the formula  $-C(O)OH$ ,  $-C(O)R$ ,  $-C(O)OR$ ,  $-C(O)NHR$ ,  $-C(O)NRR$ ;

R at each occurrence is independently selected from  $(C_1-C_6)$  alkyl,  $(C_1-C_6)$  alkenyl,  $(C_1-C_6)$  alkynyl, substituted  $(C_1-C_6)$  alkyl, substituted  $(C_1-C_6)$  alkenyl, or substituted  $(C_1-C_6)$  alkynyl; and wherein "-" is a covalent linkage.

2. A substantially pure synthetic GD2 ligand or recombinant GD2 ligand having a domain of Formula II:



wherein

X<sub>1</sub> is absent or Y or an analogue thereof;

X<sub>2</sub> is absent or C or an analogue thereof;

5 X<sub>3</sub> is G or Y or an analogue thereof;

X<sub>4</sub> is G or C or Y or an analogue thereof;

X<sub>5</sub> is I or C or an analogue thereof;

X<sub>6</sub> is T or A or an analogue thereof;

X<sub>7</sub> is N or an analogue thereof;

10 X<sub>8</sub> is Y or an analogue thereof;

X<sub>9</sub> is N or G or an analogue thereof;

X<sub>10</sub> is S or C or V or T or an analogue thereof;

X<sub>11</sub> is A or C or Y or H or S or an analogue thereof;

X<sub>12</sub> is absent or L or C or Y or an analogue thereof;

15 X<sub>13</sub> is absent or M or Y or an analogue thereof;

and wherein "-" is a covalent linkage.

3. The GD2 ligand of claim 1 or 2, wherein the ligand further comprises a cyclic linkage between any two of X<sub>1</sub> through X<sub>13</sub>.

20

4. The GD2 ligand of claim 1, wherein the ligand is selected from the group consisting of: GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; and, YCIANYNTCY.

25

5. The GD2 ligand of claim 2, wherein the domain is selected from the group consisting of: GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; and, YCIANYNTCY.

30

6. A method of treating a subject having a disease wherein disease cells express GD2, the method comprising administering to the subject an effective amount of the GD2 ligand of any one of claims 1 through 5.
- 5 7. A method of diagnosis of a disease wherein disease cells express GD2, comprising determining whether a cell from a subject binds to the GD2 ligand of any one of claims 1 through 5.
8. The method of claim 6 or 7 wherein the method is carried out *in vitro*.
- 10 9. The method of claim 6 or 7 wherein the method is carried out *in vivo*.
10. The method of claim 6, further comprising administering to the patient an effective amount of granulocyte-macrophage colony-stimulating factor.
- 15 11. A pharmaceutical composition comprising the GD2 ligand of any one of claims 1 through 5, together with an effective amount of granulocyte-macrophage colony-stimulating factor.
- 20 12. A commercial package comprising the GD2 ligand of any one of claims 1 through 5, together with instructions for using the GD2 ligand to modulate GD2 activity or detect cells expressing GD2.
- 25 13. The GD2 ligand of claim 2, wherein the GD2 ligand is a recombinant T-cell receptor.
14. The GD2 ligand of claim 13, wherein the recombinant T-cell receptor is expressed in a cytotoxic T cell line.
- 30 15. An isolated GD2 ligand substantially as hereinbefore described and with reference to the examples.

- 5
16. A method of ablating a cell line, comprising transforming the cell line to provide transformed cells that express GD2, and treating the transformed cells with an effective amount of the GD2 ligand of claim 1 or 2.
17. The use of a GD2 ligand of any one of claims 1 through 5 to formulate a medicament to treat a disease wherein diseases cells express GD2.
- 10
18. The use of a GD2 ligand according to claim 17, wherein the disease is a cancer.
19. The use of a GD2 ligand according to claim 18, wherein the cancer is a neuroblastoma.
- 15
20. A method of screening to identify or validate a putative GD2 ligand, comprising:
- a) administering a putative GD2 ligand to a system having a GD2 moiety and a p56<sup>Lck</sup> moiety available for association; and,
- 20
- f) measuring an association or functional relationship between the GD2 and the p56<sup>Lck</sup> moieties in the system.
21. The method of claim 20, wherein the putative GD2 ligand comprises a polypeptide or a non-peptidic analog such as a peptidomimetic that displays the same pharmacophore or has similar side chain functional groups.
- 25
22. The method of claim 20, wherein the putative GD2 ligand is derived from tenascin-R.
- 30
23. The method of claim 20, wherein the system is a cell expressing GD2 and p56<sup>Lck</sup>.

24. The method of claim 20, wherein the GD2 moiety is native GD2.
25. The method of claim 20, wherein the p56<sup>Lck</sup> moiety is native p56<sup>Lck</sup>.
- 5 26. The method of claim 20, wherein the association between the GD2 and the p56<sup>Lck</sup> moieties is measured by determining a kinase activity of the p56<sup>Lck</sup> moiety.
- 10



Figure 1

```

mgadgetvvl knmliginli llgsmikpse cqlevtterv qrqsveeegg ianyntsske 61
qpvvfnhvyn invpldnlcs sgleasaegv vsaedetlae ymgqtsdhes qvtfthrinf 121
pkkacpcass aqvlqellsr iemlerevsv lrdqcnancc qesaatgqld yiphcsghgn 181
fsfescgcic negwfgkncs epycplgcsc rgvcvdgqci cdseysgddc selrcptdcs 241
srglcvdgec vceeytged crelrcpgdc sgkgrcangt clceegyvge dcggrqclna 301
csgrgqceeg lcvceegyqg pdcsavappe dlrvagisdr sielewdgpm avteyvisyq 361
ptalgglqlq qrvpgdwsgv titelepglt ynisyvavis nilslpitak vathlstpgg 421
lqfktitett vevqwepfsf sfdgweisfi pknneggvia qvpsdvtsfn qtglkpgeey 481
ivnvvalkeq arspptsasv stvidgptqi lvrdsdtva fvewipprak vdfillkygl 541
vggeggrttf rlqpplsqys vqalrpgsry evsvsavrgt nesdsattqf tteidapkn1 601
rvgsrtatsl dlewdnseae vqeykvvyst lageqyhevl vprgigpttr atltdlvpgt 661
eygvgisavm nsqqsvpatm narteldspr dlmvtasset sisliwtkas gpidthyritf 721
tpssgiasev tvpkdrtsyt ltdlepgaey iisvtaergr qqslestvda ftgfrpishl 781
hfshvtsssv nitwsdpspp adrlilnysp rdeeeemnev sldatkrhav lmglqpatey 841
ivnlvavhgt vtsepivgsi ttgidppkdi tismvtdksv mvswsppvas fdyyrvsyrrp 901
tqvgrldssv vpntvtefti trlnpateye islnsvrgre eserictlvh tamdnpsvdl 961
atnitpteal lqwkavpgev enyvivilthf avagetilvd gvseefrlvd llpsthytat 1021
myatngplts gtistnfstl ldppanltas evtrqsalis wqppraeien yvltystkdg 1081
srkelivdae dtwirlegll entdytvllq aaqdtwssi tstafttggr vfphpqdcaq 1141
hlmngdtlsg vypiflngel sqklqvycdm ttdgggwivf qrrqngqtdf frkwadyrv 1201
fgnvedefwl gldnihrits qgryelrvdm rdgqeaafas ydrfsvedsr nlyklrigsy 1261
ngtagdlsy hqgrpfsted rdndvavtnc amsykgawwy knchrtlnng kygesrshsqg 1321
inwyhwkghe fsipfvemkm rpynhrlmag rkrqslqf

```

Figure 2a





Figure 2

b.



c.




Figure 2d




Figure 3




Figure 4a





Figure 4b



05 NOVEMBER 2003 05.11.03

Figure 4c





05 NOVEMBER 2003 05.11.03

Figure 5







Figure 6.




**Figure 7.****a.****b.**

**Figure 8.**

**a.**



**b.**



## SEQUENCE LISTING

10/528542

<110> MCGILL UNIVERSITY  
GAGNON, Martin  
SARAGOV, H. Uri

<120> LIGANDS OF GANGLIOSIDE GD2 AND USES THEREOF

<130> 82873-5

<140> NOT YET ASSIGNED

<141> 2003-09-19

<150> US 60/412,492

<151> 2002-09-20

<160> 23

<170> PatentIn version 3.2

<210> 1  
<211> 13  
<212> PRT  
<213> Artificial

<220>  
<223> GD2 Ligand

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = Absent or Tyr or an analogue thereof.

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> The N-terminal group may be of the formula H2N-, RHN-, or, RRN-, wherein R at each occurrence is independently selected from (C1-C6) alkyl, (C1-C6) alkenyl, (C1-C6) alkynyl, substituted (C1-C6) alkyl, substituted (C1-C6) alkenyl, or substituted (C1-C6) alkynyl.

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa = Absent or Cys or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> Xaa = Gly or Tyr or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa = Gly or Cys or Tyr or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> Xaa = Ile or Cys or an analogue thereof.

<220>  
 <221> MISC\_FEATURE  
 <222> (6)..(6)  
 <223> Xaa = Thr or Ala or an analogue thereof.

<220>  
 <221> MISC\_FEATURE  
 <222> (7)..(7)  
 <223> Xaa = Asn or an analogue thereof.

<220>  
 <221> MISC\_FEATURE  
 <222> (8)..(8)  
 <223> Xaa = Tyr or an analogue thereof.

<220>  
 <221> MISC\_FEATURE  
 <222> (9)..(9)  
 <223> Xaa = Asn or Gly or an analogue thereof.

<220>  
 <221> MISC\_FEATURE  
 <222> (10)..(10)  
 <223> Xaa = Ser or Cys or Val or Thr or an analogue thereof.

<220>  
 <221> MISC\_FEATURE  
 <222> (11)..(11)  
 <223> Xaa = Ala or Cys or Tyr or His or Ser or an analogue thereof.

<220>  
 <221> MISC\_FEATURE  
 <222> (12)..(12)  
 <223> Xaa = absent or Leu or Cys or Tyr or an analogue thereof.

<220>  
 <221> MISC\_FEATURE  
 <222> (13)..(13)  
 <223> Xaa = absent or Met or Tyr or an analogue thereof.

<220>  
 <221> MOD\_RES  
 <222> (13)..(13)  
 <223> C-terminal grp is of the formula -C(O)OH, -C(O)R, -C(O)OR,  
 -C(O)NHR, -C(O)NRR; wherein each R is independently selected from  
 (C1-C6) alkyl, (C1-C6) alkenyl, (C1-C6) alkynyl, substituted (C1-C6)  
 alkyl, substituted (C1-C6) alkenyl, or substituted (C1-C6) alkynyl.

<400> 1  
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 1 5 10

<210> 2  
 <211> 13  
 <212> PRT  
 <213> Artificial

<220>  
 <223> GD2 Ligand

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = Absent or Tyr or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa = Absent or Cys or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> Xaa = Gly or Tyr or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa = Gly or Cys or Tyr or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> Xaa = Ile or Cys or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (6)..(6)  
<223> Xaa = Thr or Ala or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (7)..(7)  
<223> Xaa = Asn or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (8)..(8)  
<223> Xaa = Tyr or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (9)..(9)  
<223> Xaa = Asn or Gly or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> Xaa = Ser or Cys or Val or Thr or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (11)..(11)  
<223> Xaa = Ala or Cys or Tyr or His or Ser or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (12)..(12)  
<223> Xaa = Absent or Leu or Cys or Tyr or an analogue thereof.

<220>  
<221> MISC\_FEATURE  
<222> (13)..(13)  
<223> Xaa = Absent or Met or Tyr or an analogue thereof.

<400> 2  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 3  
<211> 11  
<212> PRT  
<213> Artificial

<220>  
<223> GD2 Ligand

<400> 3  
Gly Gly Ile Thr Asn Tyr Asn Ser Ala Leu Met  
1 5 10

<210> 4  
<211> 13  
<212> PRT  
<213> Artificial

<220>  
<223> GD2 Ligand

<400> 4  
Tyr Cys Gly Gly Ile Thr Asn Tyr Asn Ser Ala Cys Tyr  
1 5 10

<210> 5  
<211> 10  
<212> PRT  
<213> Artificial

<220>  
<223> GD2 Ligand

<400> 5  
Tyr Cys Ile Thr Asn Tyr Asn Ser Cys Tyr  
1 5 10

<210> 6  
<211> 11  
<212> PRT  
<213> Artificial

<220>  
<223> GD2 Ligand

<400> 6  
Tyr Cys Gly Gly Ile Thr Asn Tyr Asn Cys Tyr  
1 5 10



<210> 7  
<211> 10  
<212> PRT  
<213> Artificial

<220>  
<223> GD2 Ligand

<400> 7  
Tyr Cys Thr Asn Tyr Gly Val His Cys Tyr  
1 5 10

<210> 8  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> GD2 Ligand

<400> 8  
Tyr Cys Thr Asn Tyr Gly Val Cys Tyr  
1 5

<210> 9  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> GD2 Ligand

<400> 9  
Gly Gly Ile Ala Asn Tyr Asn Thr Ser  
1 5

<210> 10  
<211> 11  
<212> PRT  
<213> Artificial

<220>  
<223> GD2 Ligand

<400> 10  
Tyr Cys Gly Gly Ile Ala Asn Tyr Asn Cys Tyr  
1 5 10

<210> 11  
<211> 13  
<212> PRT  
<213> Artificial

<220>  
<223> GD2 Ligand

<400> 11  
Tyr Cys Gly Gly Ile Ala Asn Tyr Asn Thr Ser Cys Tyr  
1 5 10

<210> 12  
<211> 10  
<212> PRT  
<213> Artificial

<220>  
<223> GD2 Ligand

<400> 12  
Tyr Cys Ile Ala Asn Tyr Asn Thr Cys Tyr  
1 5 10

<210> 13  
<211> 5  
<212> PRT  
<213> Artificial

<220>  
<223> Spanning sequence for peptide analogs that actively inhibit  
GD2-mAb 3F8 interactions.

<400> 13  
Ile Thr Asn Tyr Asn  
1 5

<210> 14  
<211> 5  
<212> PRT  
<213> Artificial

<220>  
<223> Spanning sequence for peptide analogs that actively inhibit  
GD2-mAb 3F8 interactions.

<400> 14  
Ile Ala Asn Tyr Asn  
1 5

<210> 15  
<211> 11  
<212> PRT  
<213> Artificial

<220>  
<223> Peptide Mimic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(11)  
<223> Peptide is cyclic.

<400> 15  
Cys Gly Gly Ile Thr Asn Tyr Asn Ser Ala Cys  
1 5 10

<210> 16  
<211> 8  
<212> PRT  
<213> Artificial

<220>  
<223> Peptide Mimic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(8)  
<223> Peptide is cyclic.

<400> 16  
Cys Ile Thr Asn Tyr Asn Ser Cys  
1 5

<210> 17  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> Peptide Mimic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(9)  
<223> Peptide is cyclic.

<400> 17  
Cys Gly Gly Ile Thr Asn Tyr Asn Cys  
1 5

<210> 18  
<211> 8  
<212> PRT  
<213> Artificial

<220>  
<223> Peptide Mimic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(8)  
<223> Peptide is cyclic.

<400> 18  
Cys Thr Asn Tyr Gly Val His Cys  
1 5

<210> 19  
<211> 7  
<212> PRT  
<213> Artificial

<220>  
<223> Peptide Mimic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(7)  
<223> Peptide is cyclic.

<400> 19  
Cys Thr Asn Tyr Gly Val Cys  
1 5

<210> 20  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> Peptide Mimic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(9)  
<223> Peptide is cyclic.

<400> 20  
Cys Gly Gly Ile Ala Asn Tyr Asn Cys  
1 5

<210> 21  
<211> 11  
<212> PRT  
<213> Artificial

<220>  
<223> Peptide Mimic

<400> 21  
Cys Gly Gly Ile Ala Asn Tyr Asn Thr Ser Cys  
1 5 10

<210> 22  
<211> 8  
<212> PRT  
<213> Artificial

<220>  
<223> Peptide mimic.

<220>  
<221> MISC\_FEATURE  
<222> (1)..(8)  
<223> Peptide is cyclic.

&lt;400&gt; 22

Cys Ile Ala Asn Tyr Asn Thr Cys

1

5

&lt;210&gt; 23

&lt;211&gt; 1358

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

Met Gly Ala Asp Gly Glu Thr Val Val Leu Lys Asn Met Leu Ile Gly  
1 5 10 15Ile Asn Leu Ile Leu Leu Gly Ser Met Ile Lys Pro Ser Glu Cys Gln  
20 25 30Leu Glu Val Thr Thr Glu Arg Val Gln Arg Gln Ser Val Glu Glu Glu  
35 40 45Gly Gly Ile Ala Asn Tyr Asn Thr Ser Ser Lys Glu Gln Pro Val Val  
50 55 60Phe Asn His Val Tyr Asn Ile Asn Val Pro Leu Asp Asn Leu Cys Ser  
65 70 75 80Ser Gly Leu Glu Ala Ser Ala Glu Gln Glu Val Ser Ala Glu Asp Glu  
85 90 95Thr Leu Ala Glu Tyr Met Gly Gln Thr Ser Asp His Glu Ser Gln Val  
100 105 110Thr Phe Thr His Arg Ile Asn Phe Pro Lys Lys Ala Cys Pro Cys Ala  
115 120 125Ser Ser Ala Gln Val Leu Gln Glu Leu Leu Ser Arg Ile Glu Met Leu  
130 135 140Glu Arg Glu Val Ser Val Leu Arg Asp Gln Cys Asn Ala Asn Cys Cys  
145 150 155 160Gln Glu Ser Ala Ala Thr Gly Gln Leu Asp Tyr Ile Pro His Cys Ser  
165 170 175Gly His Gly Asn Phe Ser Phe Glu Ser Cys Gly Cys Ile Cys Asn Glu  
180 185 190Gly Trp Phe Gly Lys Asn Cys Ser Glu Pro Tyr Cys Pro Leu Gly Cys  
195 200 205Ser Ser Arg Gly Val Cys Val Asp Gly Gln Cys Ile Cys Asp Ser Glu  
210 215 220Tyr Ser Gly Asp Asp Cys Ser Glu Leu Arg Cys Pro Thr Asp Cys Ser  
225 230 235 240Ser Arg Gly Leu Cys Val Asp Gly Glu Cys Val Cys Glu Glu Pro Tyr  
245 250 255

Thr Gly Glu Asp Cys Arg Glu Leu Arg Cys Pro Gly Asp Cys Ser Gly  
 260 265 270  
 Lys Gly Arg Cys Ala Asn Gly Thr Cys Leu Cys Glu Glu Gly Tyr Val  
 275 280 285  
 Gly Glu Asp Cys Gly Gln Arg Gln Cys Leu Asn Ala Cys Ser Gly Arg  
 290 295 300  
 Gly Gln Cys Glu Glu Gly Leu Cys Val Cys Glu Glu Gly Tyr Gln Gly  
 305 310 315 320  
 Pro Asp Cys Ser Ala Val Ala Pro Pro Glu Asp Leu Arg Val Ala Gly  
 325 330 335  
 Ile Ser Asp Arg Ser Ile Glu Leu Glu Trp Asp Gly Pro Met Ala Val  
 340 345 350  
 Thr Glu Tyr Val Ile Ser Tyr Gln Pro Thr Ala Leu Gly Gly Leu Gln  
 355 360 365  
 Leu Gln Gln Arg Val Pro Gly Asp Trp Ser Gly Val Thr Ile Thr Glu  
 370 375 380  
 Leu Glu Pro Gly Leu Thr Tyr Asn Ile Ser Val Tyr Ala Val Ile Ser  
 385 390 395 400  
 Asn Ile Leu Ser Leu Pro Ile Thr Ala Lys Val Ala Thr His Leu Ser  
 405 410 415  
 Thr Pro Gln Gly Leu Gln Phe Lys Thr Ile Thr Glu Thr Thr Val Glu  
 420 425 430  
 Val Gln Trp Glu Pro Phe Ser Phe Ser Phe Asp Gly Trp Glu Ile Ser  
 435 440 445  
 Phe Ile Pro Lys Asn Asn Glu Gly Gly Val Ile Ala Gln Val Pro Ser  
 450 455 460  
 Asp Val Thr Ser Phe Asn Gln Thr Gly Leu Lys Pro Gly Glu Glu Tyr  
 465 470 475 480  
 Ile Val Asn Val Val Ala Leu Lys Glu Gln Ala Arg Ser Pro Pro Thr  
 485 490 495  
 Ser Ala Ser Val Ser Thr Val Ile Asp Gly Pro Thr Gln Ile Leu Val  
 500 505 510  
 Arg Asp Val Ser Asp Thr Val Ala Phe Val Glu Trp Ile Pro Pro Arg  
 515 520 525  
 Ala Lys Val Asp Phe Ile Leu Leu Lys Tyr Gly Leu Val Gly Gly Glu  
 530 535 540  
 Gly Gly Arg Thr Thr Phe Arg Leu Gln Pro Pro Leu Ser Gln Tyr Ser  
 545 550 555 560  
 Val Gln Ala Leu Arg Pro Gly Ser Arg Tyr Glu Val Ser Val Ser Ala  
 565 570 575

Val Arg Gly Thr Asn Glu Ser Asp Ser Ala Thr Thr Gln Phe Thr Thr  
 580 585 590  
 Glu Ile Asp Ala Pro Lys Asn Leu Arg Val Gly Ser Arg Thr Ala Thr  
 595 600 605  
 Ser Leu Asp Leu Glu Trp Asp Asn Ser Glu Ala Glu Val Gln Glu Tyr  
 610 615 620  
 Lys Val Val Tyr Ser Thr Leu Ala Gly Glu Gln Tyr His Glu Val Leu  
 625 630 635 640  
 Val Pro Arg Gly Ile Gly Pro Thr Thr Arg Ala Thr Leu Thr Asp Leu  
 645 650 655  
 Val Pro Gly Thr Glu Tyr Gly Val Gly Ile Ser Ala Val Met Asn Ser  
 660 665 670  
 Gln Gln Ser Val Pro Ala Thr Met Asn Ala Arg Thr Glu Leu Asp Ser  
 675 680 685  
 Pro Arg Asp Leu Met Val Thr Ala Ser Ser Glu Thr Ser Ile Ser Leu  
 690 695 700  
 Ile Trp Thr Lys Ala Ser Gly Pro Ile Asp His Tyr Arg Ile Thr Phe  
 705 710 715 720  
 Thr Pro Ser Ser Gly Ile Ala Ser Glu Val Thr Val Pro Lys Asp Arg  
 725 730 735  
 Thr Ser Tyr Thr Leu Thr Asp Leu Glu Pro Gly Ala Glu Tyr Ile Ile  
 740 745 750  
 Ser Val Thr Ala Glu Arg Gly Arg Gln Gln Ser Leu Glu Ser Thr Val  
 755 760 765  
 Asp Ala Phe Thr Gly Phe Arg Pro Ile Ser His Leu His Phe Ser His  
 770 775 780  
 Val Thr Ser Ser Ser Val Asn Ile Thr Trp Ser Asp Pro Ser Pro Pro  
 785 790 795 800  
 Ala Asp Arg Leu Ile Leu Asn Tyr Ser Pro Arg Asp Glu Glu Glu Glu  
 805 810 815  
 Met Met Glu Val Ser Leu Asp Ala Thr Lys Arg His Ala Val Leu Met  
 820 825 830  
 Gly Leu Gln Pro Ala Thr Glu Tyr Ile Val Asn Leu Val Ala Val His  
 835 840 845  
 Gly Thr Val Thr Ser Glu Pro Ile Val Gly Ser Ile Thr Thr Gly Ile  
 850 855 860  
 Asp Pro Pro Lys Asp Ile Thr Ile Ser Asn Val Thr Lys Asp Ser Val  
 865 870 875 880  
 Met Val Ser Trp Ser Pro Pro Val Ala Ser Phe Asp Tyr Tyr Arg Val  
 885 890 895

Ser Tyr Arg Pro Thr Gln Val Gly Arg Leu Asp Ser Ser Val Val Pro  
 900 905 910  
 Asn Thr Val Thr Glu Phe Thr Ile Thr Arg Leu Asn Pro Ala Thr Glu  
 915 920 925  
 Tyr Glu Ile Ser Leu Asn Ser Val Arg Gly Arg Glu Glu Ser Glu Arg  
 930 935 940  
 Ile Cys Thr Leu Val His Thr Ala Met Asp Asn Pro Val Asp Leu Ile  
 945 950 955 960  
 Ala Thr Asn Ile Thr Pro Thr Glu Ala Leu Leu Gln Trp Lys Ala Pro  
 965 970 975  
 Val Gly Glu Val Glu Asn Tyr Val Ile Val Leu Thr His Phe Ala Val  
 980 985 990  
 Ala Gly Glu Thr Ile Leu Val Asp Gly Val Ser Glu Glu Phe Arg Leu  
 995 1000 1005  
 Val Asp Leu Leu Pro Ser Thr His Tyr Thr Ala Thr Met Tyr Ala  
 1010 1015 1020  
 Thr Asn Gly Pro Leu Thr Ser Gly Thr Ile Ser Thr Asn Phe Ser  
 1025 1030 1035  
 Thr Leu Leu Asp Pro Pro Ala Asn Leu Thr Ala Ser Glu Val Thr  
 1040 1045 1050  
 Arg Gln Ser Ala Leu Ile Ser Trp Gln Pro Pro Arg Ala Glu Ile  
 1055 1060 1065  
 Glu Asn Tyr Val Leu Thr Tyr Lys Ser Thr Asp Gly Ser Arg Lys  
 1070 1075 1080  
 Glu Leu Ile Val Asp Ala Glu Asp Thr Trp Ile Arg Leu Glu Gly  
 1085 1090 1095  
 Leu Leu Glu Asn Thr Asp Tyr Thr Val Leu Leu Gln Ala Ala Gln  
 1100 1105 1110  
 Asp Thr Thr Trp Ser Ser Ile Thr Ser Thr Ala Phe Thr Thr Gly  
 1115 1120 1125  
 Gly Arg Val Phe Pro His Pro Gln Asp Cys Ala Gln His Leu Met  
 1130 1135 1140  
 Asn Gly Asp Thr Leu Ser Gly Val Tyr Pro Ile Phe Leu Asn Gly  
 1145 1150 1155  
 Glu Leu Ser Gln Lys Leu Gln Val Tyr Cys Asp Met Thr Thr Asp  
 1160 1165 1170  
 Gly Gly Gly Trp Ile Val Phe Gln Arg Arg Gln Asn Gly Gln Thr  
 1175 1180 1185  
 Asp Phe Phe Arg Lys Trp Ala Asp Tyr Arg Val Gly Phe Gly Asn  
 1190 1195 1200



Val Glu Asp Glu Phe Trp Leu Gly Leu Asp Asn Ile His Arg Ile	
1205	1210 1215
Thr Ser Gln Gly Arg Tyr Glu Leu Arg Val Asp Met Arg Asp Gly	
1220	1225 1230
Gln Glu Ala Ala Phe Ala Ser Tyr Asp Arg Phe Ser Val Glu Asp	
1235	1240 1245
Ser Arg Asn Leu Tyr Lys Leu Arg Ile Gly Ser Tyr Asn Gly Thr	
1250	1255 1260
Ala Gly Asp Ser Leu Ser Tyr His Gln Gly Arg Pro Phe Ser Thr	
1265	1270 1275
Glu Asp Arg Asp Asn Asp Val Ala Val Thr Asn Cys Ala Met Ser	
1280	1285 1290
Tyr Lys Gly Ala Trp Trp Tyr Lys Asn Cys His Arg Thr Asn Leu	
1295	1300 1305
Asn Gly Lys Tyr Gly Glu Ser Arg His Ser Gln Gly Ile Asn Trp	
1310	1315 1320
Tyr His Trp Lys Gly His Glu Phe Ser Ile Pro Phe Val Glu Met	
1325	1330 1335
Lys Met Arg Pro Tyr Asn His Arg Leu Met Ala Gly Arg Lys Arg	
1340	1345 1350
Gln Ser Leu Gln Phe	
1355	

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>82873-5</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/CA 03/01389</b>	International filing date (day/month/year) <b>19/09/2003</b>	(Earliest) Priority Date (day/month/year) <b>20/09/2002</b>
Applicant <b>MCGILL UNIVERSITY</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 7 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ Certain claims were found unsearchable (See Box I).

3. ☒ Unity of invention is lacking (see Box II).

**4. With regard to the title,**

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

**5. With regard to the abstract,**

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

**6. The figure of the drawings to be published with the abstract is Figure No.**

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 03/01389

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-19 (completely)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 6, 8-10, 17-19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claim 7 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 03/01389

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K7/04 C07K7/64 A61K38/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, BIOSIS, WPI Data, PAJ, PASCAL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CARNEMOLLA B ET AL: "HUMAN TENASCIN-R" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 14, 5 April 1996 (1996-04-05), pages 8157-8160, XP000606961 ISSN: 0021-9258 figure 1  ----- -/--	2,5



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

14 January 2004

Date of mailing of the international search report

14.06.04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Lanzrein, M

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PROBSTMEIER RAINER ET AL: "Tenascin-C inhibits betal integrin-dependent cell adhesion and neurite outgrowth on fibronectin by a disialoganglioside-mediated signaling mechanism"            GLYCOBIOLOGY,            vol. 9, no. 2, February 1999 (1999-02),            pages 101-104, XP009023657            ISSN: 0959-6658            page 107, right-hand column, lines 10-15;            figure 4</p>	2,5
A	<p>-----</p> <p>TSAO CHUN-YEN ET AL: "Identification of GD2 ganglioside peptide mimics by using phage display peptide libraries"            PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL,            vol. 43, March 2002 (2002-03), page 280,            XP001157107            93rd Annual Meeting of the American Association for Cancer Research; San Francisco, California, USA; April 06-10, 2002, March, 2002            ISSN: 0197-016X            the whole document</p>	1-19
A	<p>-----</p> <p>CHEUNG NAI-KONG V ET AL:            "Disialoganglioside G-D2 anti-idiotypic monoclonal antibodies"            INTERNATIONAL JOURNAL OF CANCER,            vol. 54, no. 3, 1993, pages 499-505,            XP009023655            ISSN: 0020-7136            page 504, right-hand column, last paragraph; tables 4,5</p>	1-19
A	<p>-----</p> <p>TUR MEHMET KEMAL ET AL: "An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines"            INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE,            vol. 8, no. 5, November 2001 (2001-11),            pages 579-584, XP009023656            ISSN: 1107-3756            figures 3,4</p>	1-19
A	<p>-----</p> <p>US 5 935 821 A (CHATTERJEE MALAYA ET AL)            10 August 1999 (1999-08-10)</p> <p>-----</p> <p style="text-align: center;">-/--</p>	

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>SARAGОВI H URI ET AL: "Cell surface GD2 gangliosides act as genuine receptors: ligands activate p56Lck signal transduction and regulate tumorigenesis in vitro and in vivo." FASEB JOURNAL, vol. 17, no. 4-5, March 2003 (2003-03), page Abstract No. 363.4, XP009023658 FASEB Meeting on Experimental Biology: Translating the Genome; San Diego, CA, USA; April 11-15, 2003 ISSN: 0892-6638 (ISSN print) the whole document</p> <p>-----</p>	1-19

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/CA 03/01389

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5935821	A	10-08-1999	US 5612030 A	18-03-1997
			US 5977316 A	02-11-1999
			US 6509016 B1	21-01-2003
			AU 713331 B2	02-12-1999
			AU 5414996 A	07-08-1996
			CA 2210158 A1	25-07-1996
			EP 0807176 A2	19-11-1997
			JP 2002508651 T	19-03-2002
			WO 9622373 A2	25-07-1996
			US 2003114398 A1	19-06-2003



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**